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Glia cell line-derived neurotrophic factor (GDNF) is a survival factor for subpopulations of neurons, including somatic and autonomic motor neurons. These neurons
depend, in part, on GDNF that is synthesized and secreted by their target tissues. It has
been shown that a number of tissues in the periphery express GDNF and these target tissues
differ in their composition, function, and in the case of different muscle cell types, their
contractile characteristics. Whether the processes regulating GDNF production in these
different tissues is similar or different is poorly understood. The broad goal of this study is
to examine factors that normally regulate GDNF expression in skeletal and cardiac
muscles, with an emphasis on comparing the similarities and differences in these voluntary
and involuntary muscles in relation to GDNF production. Previous studies with nervemuscle co-cultures in our laboratory have shown that GDNF protein levels are reduced
when skeletal muscle is in contact with cholinergic nerves. Thus, the hypothesis being
tested is that cellular activation by neural cells, via neurotransmitter effects, regulates
GDNF expression in voluntary and involuntary muscles. Some cultures were electrically
stimulated (30min to 48h) to determine whether electrical activity is an important regulator
of neurotrophic factor production. Samples of culture medium and cells were collected
between 0h and 48h. The results show that acetylcholine inhibits GDNF secretion in both

cell types, while electrical stimulation has opposing effects on GDNF production, where
GDNF levels increase with long-term electrical stimulation in skeletal muscle and decrease
with long-term electrical stimulation in cardiac muscle. When cardiac muscle cells were
tested alone, norepinephrine was found to stimulate production of GDNF but inhibit
production of nerve growth factor (NGF). Electrical stimulation had a similar effect on
NGF and GDNF production in cardiac muscle cells. This work suggests that GDNF
expression may be regulated differently in cardiac and skeletal muscle. Understanding the
regulation of GDNF production in these tissues will provide a better understanding of how
these processes may be modulated therapeutically.
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CHAPTER 1
INTRODUCTION

1.1.

OVERVIEW
The somatic and autonomic nervous systems are the major branches of the

nervous system that operate in the periphery. Both systems consist of motor nerves, but
differ in functional characteristics including their origin, efferent impulse transmission
pathways, target effectors, and target responses in terms of excitatory or inhibitory effects.
Thus, the two systems differ in the type of control they exert. While the somatic system is
voluntary and provides conscious control of voluntary (skeletal) muscle, the autonomic
nervous system is involuntary and exerts unconscious control of involuntary (cardiac and
smooth) muscles. Voluntary and involuntary target muscles differ in their composition,
location, and function. In mammals including humans, skeletal muscles are distributed
throughout the body, whereas, cardiac muscles are found only in the heart (Sherwood,
2010).
In order to maintain optimal motor movement, nerves, muscles, and other
elements at the synapse should all function synergistically. This may include, but is not
limited to proper neurotransmitter release, expression of synaptic receptors, and sufficient
supply of target-derived neurotrophic factors. The neurotrophic factors are the family of
proteins that have been proven to be capable of providing survival and maintenance of
neuronal populations (Silva and Wang, 2011). However, little is known about processes
that normally regulate levels of expression for muscle target-derived neurotrophic factors.
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Moreover, it is not clear whether a given neurotrophic factor is regulated in a similar or
different ways within different muscle types.
This study utilizes skeletal muscle and cardiac muscle as models for voluntary
and involuntary muscles, respectively. We have examined the synthesis and secretion of
glial cell line-derived neurotrophic factor (GDNF) in these two types of muscle. Nerve
growth factor (NGF) was also examined in cardiomyocytes. Understanding the similarities
and differences in regulation of the neurotrophic factors in different types of targets, in this
case, voluntary and involuntary muscles, will give insight into how the neurotrophic factors
can be modulated in therapeutic settings.

1.2. NEUROTROPHIC FACTORS
Neurotrophic factors are a family of proteins that are responsible for the growth
and survival of developing neurons and the maintenance of mature neurons. Neurotrophic
factors are classified in several subgroups including the neurotrophin family and glial cell
line-derived neurotrophic factor (GDNF) family.
The neurotrophin family is a group of neurotrophic factors which is comprised of
the structurally related proteins: nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) (Henderson, 1996;
Allen and Dawbarn, 2006). Each member of the neurotrophin family binds with high
affinity to the receptor tyrosine kinase of the Trk family, specifically, NGF and NT-3 act
via Trk-A and Trk-C, respectively whereas BDNF and NT-4/5 bind to the Trk-B receptor.
All neurotrophins also exert trophic action by binding to a common receptor, p75
(Henderson, 1996; Lu, 2003).
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Glial cell line-derived neurotrophic factor (GDNF) family ligands are distant
members of the transforming growth factor beta (TGF-) superfamily, since each member
in the GDNF family ligand contains seven cysteine repeated amino acids at the same
distance as the other members of the TGF- superfamily (Lin et al., 1993). The GDNF
family includes four members: GDNF, neurturin (NTRN), artermin (ARTN), and
persephin (PSPN). All members of the GDNF family induce signaling through binding
with high affinity to GDNF family receptor alpha (GFR-1-4). Specifically, GDNF binds
to GFR-1, NTRN binds to GFR-2, ARTN binds to GFR-3, and PSPN binds to GFR4. Each ligand binds to its receptor anchored to glycosyl- phosphatidylinositol (GPI). The
ligand-receptor complex signals through receptor tyrosine kinase RET, to induce neuronal
differentiation and survival (Saarma, 2000; Sariola and Saarma, 2003).
1.2.1 General characteristics and functions of neurotrophic factors
Neurotrophic factors are synthesized in neuronal and non-neuronal tissues.
Neurotrophic factor localization studies have shown that a target tissue can express more
than one type of trophic factor, as seen in skeletal muscle that expresses BDNF, NT-3, and
GDNF (Funakoshi et al., 1993; Kingham and Terenghi, 2006). Additionally, a single
trophic factor can be synthesized in several different target tissues (Table 1). Furthermore,
depending on the demand, expression of neurotrophic factors can be regulated in activitydependent manner or constitutively secreted (Schinder and Poo, 2000; Lu, 2003). The
neurotrophic factors have been found to provide their trophic effect in several ways
including axonal guidance during development, neuronal survival during programmed cell
death, synaptic transmission and maintenance in adults, and facilitation of nerve
regeneration (Houenou et al., 1996). While other neurotrophic factors have been shown to
3

depend on each other to exert their trophic effects (Aszmann et al., 2002; Gould and
Enomoto, 2009), in most cases, a single neurotrophic factor can elicit a neurotrophic effect
alone. NGF and GDNF (to be discussed in later sections) are examples of neurotrophic
factors that each acts independently to provide trophic effects to the nervous system (Bohn,
2004; Govoni, 2011).

1.3. OVERVIEW OF NEURAL-TARGET INTERACTION
Most, if not all, communications between the nervous system and the periphery
are carried out through the interaction between a nerve and its target at the synapse. The
peripheral synapse is a critical anatomical structure where, the connection between the
nerve and its target occurs and signal transmission takes place. This allows the movements
of the body upon which life depends. These bodily movements include muscle contraction,
breathing, swallowing, heartbeat, and walking. The efficient communication between a
nerve and its target can be disrupted in neurodegenerative diseases, aging, or by nerve
damage (Aszmann et al., 2002; Lie and Weis, 1998). However, studies have shown that
reinnervation can take place, although it is not common that natural reinnervation can
completely restore the original synaptic integrity. Administration of neurotrophic factors
have been shown to enhance reinnervation following denervation or nerve damage
(Michalski et al., 2008; Zhang et al., 2009). It has been also shown that the process of
reinnervation shows similar characteristics to that of neuronal development. These
characteristics include the expression of growth associated protein 43 (GAP43), suggesting
that dysfunction, aging, or damaged nerve switches from transmitting function to growth
mode when making new connections to restore synaptic structure (Fu and Gordon, 1997)
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Table 1.1: NGF and GDNF expression in various target and non-target tissues
NERVE GROWTH

GLIAL CELL LINE-DERIVED NEUROTOPHIC

FACTOR

FACTORS

Tissue

Citation

Tissue

Tissues/Cells in the CNS and
PNS

Citation

Tissues/Cells in the CNS and
PNS

Cortex and hippocampus

Mufson et al., 1999*

Striatum, substantia nigra

Glia, ependymal, endothelia

Thoenen et al., 1995*

basal ganglia, purkinje neurons

Springer et al., 1995

Dorsal root ganglia

Hiltunen et al., 2001*

brainstem, cerebellum, cerebral

Retina and the Schwann cells

Micera et al., 2004*

cortex

Nosrat et al., 1996

of the iris

Rush et al.,1984*

Thalamus

Hase et al., 1999

Smooth muscle cells

Schäper et al., 2009*

Spinal cord

McCollough and

Heart/ heart cells

Hiltunen et al., 2001*

Spitsbergen, 2013

Kaye et al., 2000

Superior cervical ganglia

Trupp et al., 1995

Epithelialcells, fibroblasts

Schäper et al., 2009*

Dorsal root ganglia

Trupp et al., 1995

Lung

Freund et al., 2004*

Microglia

Matsushita et al., 2008

Colon

Stanzel et al., 2008*

Astrocyte and Schwann cells

Zhao et al., 2004

Retina

Kretzet et al., 2006

Nasal cavity (epithelium)

Springer et al., 1995,

Anterior pituitary gland

Calzà et al., 1997*

inner year and year canal

Nosrat et al.,1996

(mammotroph cells)

Missale et al., 1996*

Heart/cardiomyocyte

Martinel et al., 2007
Gyorkos and Spitsbergen,

Skeletal muscle

2014

Glands

Submaxillary/submandibular
sublingual glands

Levi-Montalcine, 1951*

Smooth muscle

Nosrat et al., 1996

Granular convoluted tubule cells

Mathison et al.,1995*

Lung

Salivary glands

Gastrointestinal tract

Thyroid gland

Nam et al., 2007*
Van der Laan et al.,
1995*

Nagano and Suzuki, 2003
Trupp et al., 1995;
Moore et al., 1996

Pancreas

Miralles et al., 1998*

Gastro-enteric tract, liver

Govon et al., 2011

Other areas

Other areas
Adrenal gland

Biological fluids

Govon et al., 2011

Trupp et al., 1995
Nosrat et al., 1996

(source of GDNF isn't known)

Tangue

Rind et al., 2005

Spleen, prostate, and epidemis

Govon et al., 2011

Teeth

Nosrat et al., 1996

Mast cell, macrophages and

Lambiase et al., 2004*

Uteric buds

Moore et al., 1996

lympocytes

Leon et al., 1994*

Reproductive organs

Govon et al., 2011

Pichel et al., 1996
Spleen, Testes

Suzuki et al., 1998

* Citations are also found in Govoni, G., Pascalea, A., Amadioa, M., Calvillo, L., D’Elia, E., Ceredad, C., Fantuccie,
P., Ceronif, M., Vanolih, E., 2011. NGF and heart: Is there a role in heart disease? Pharmacological Res. 63: 266277.
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It can be that suggested understanding of nerve development could provide an alternative
way to examine nerve regeneration. Therefore, a better understanding of origin, progenitor
cells, trophic effects, and guidance cues in the process of nerve-target formation can add
information and give insight into the process of reinnervation.
1.3.1. Somatic nervous system development
Three types of cells are present at the neuromuscular junction (NMJ): motor
neuron, muscle fiber, and Schwann cells (Band-Saberi et al., 1996; Hasan, 2013). In early
development these cells originate from different types of cell layers but meet to form the
NMJ: motor neurons are formed from somata in the neural tube while Schwann cells
develop from neural crest cells. Mesodemal cells give rise to myogenic cells, which in turn
differentiate into myoblasts; finally the myoblasts fuse to form myotubes (Band-Saberi et
al., 1996). Since each myoblast contains a single nucleus, the fusion of myoblasts results
in multinucleated myotubes, a specific characteristic of skeletal muscle fiber. A pool of
motor neurons originates from the ventral horn of the spinal cord, then the pool of motor
neurons converges into a single motor neuron that grows an axon and innervates its
appropriate skeletal muscle fibers (Burden, 1998). These observations suggest that there
should be guidance cues for axon pathfinding towards appropriate targets. The complex of
target-derived GDNF, its receptor GFR1, and neural cell adhesion molecules (NCAM)
was reported to play a role in motor neuron axonal guidance towards appropriate targets
(Paratcha et al., 2003; Paratcha and Ledda, 2008). Once a motor axon growth cone contacts
a newly formed myotube, differentiation of the presynaptic and postsynaptic apparatus
begins. The synaptic transmission molecules include acetylcholine (ACh), acetylcholine
6

receptors

induction

activity

(ARIA),

ion

channels,

neuregulin,

integrins,

acetylcholinesterase (AChE), heparan sulfate proteoghylcan, neural cell adhesion
molecules (NCAM), rapsyn, muscle-specific kinase (MuSK), acetylcholine receptors
(AChRs), sodium channels, and other synaptic molecules (Meier and Wallace, 1998).
Interestingly, neurotrophic factors, such as GDNF, were found to be involved in this motor
nerve signaling and synaptic transmission (to be discussed in later sections).
1.3.2. Autonomic nervous system development
The development of the heart takes place independently of its innervation and it
is the first organ to form and function during development. Studies also have confirmed
that heart formation is conserved in all vertebrates (Yutzey and Kirby, 2002). Cardiac
progenitor cells have been identified even before gastrulation. In chick embryo, the cardiac
progenitors can be seen in the primitive streak as early as 10-12 hours after fertilization
and the beating heart tube is apparent within 33-38 hours (Yutzey and Kirby, 2002). In
mouse models, mapping studies show the progenitor heart cells as early as embryonic day
10. The p75NTR neutrophin receptor, and vagal nerves can be observed 2-days following
heart formation (Hildreth et al., 2008).
The origin of sympathetic and parasympathetic neural cells during development
have been examined and extensively reviewed (Hasan et al., 2013; Kimura et al., 2012;
San Mauro, 2009; Mitchell, 1953; Olshansky et al., 2008). Briefly, both parasympathetic
and sympathetic neurons arise from neural crest cells that migrate from the neural fold and
neural tube respectively and subsequently differentiate into mature neurons (Hasan et al.,
2013; Kimura et al., 2012; Serbedzija et al., 1990). The neural crest migration,
differentiation, early ganglia formation, and axonal projections, depend on guidance cues
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including neurotrophic factors, specifically, NGF (Gammill et al., 2005; Hasan, 2013;
Kimura et al., 2012; Levi-Montalcini, 1987). However, the arrival of neural crest cells that
form parasympathetic nerves precede those that form sympathetic nerves (Hildreth et al.,
2008); in other words, the cholinergic inhibition of heart rate begins to function earlier than
the sympathetic stimulation of the heart (Hasan, 2013).
The mature sympathetic and parasympathetic pathways contain two neurons,
preganglionic and postganglionic. Parasympathetic neurons arise from medial medullary
site nuclei: nucleus ambiguous, nucleus tractus solitarius, and dorsal motor nucleus. This
vagus nerve extends from the medulla and synapses with postganglionic nerves that
innervate the heart via ganglia located in cardiac fat pads in the atria (Olshansky et al.,
2008). Sympathetic neurons originate in the spinal cord and emerge in the spinal nerve
derived from thoracic (T) regions, T-1 through T-3. Although, preganglionic fibers of both
divisions synapse with postganglionic fibers at the ganglia, the location of the ganglia
differs, with parasympathetic ganglia located within the heart epicardium and sympathetic
ganglia located near the spinal cord (Olshansky et al., 2008).
Parasympathetic and sympathetic preganglionic neurons release ACh at the
ganglia. The released ACh binds to nicotinic acetylcholine receptors (nAChRs) located on
both postganglionic neurons. Sympathetic postganglionic fibers release norepinephrine
(NE) which activates adrenergic receptors. Parasympathetic postganglionic neurons
release ACh which interacts with muscarinic acetycholine receptors (mAChRs). Although
sympathetic and parasympathetic fibers are distributed in both atria and ventricles of the
heart, their innervation density varies from region to region: The conduction system is
innervated by both divisions (Crick et al.,1999; Kimura et al., 2012), but in the sinoatrial
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and sinoventricular nodes, the cholinergic fibers are more concentrated than the adrenergic
fibers (Kawano et al., 2003; Kimura et al., 2012). Likewise, muscarinic type 2 receptors
(M2) are the most abundant receptors in atria, possibly reflecting the abundance of
cholinergic fibers (Olshansky et al., 2008). Taken together, compared to somatic neural
system innervation, cardiac nervous system innervation is complex. The complexity of
innervation of the heart may also suggest the strong influence of the extrinsic nervous
system on the heart’s performance at the beat-to-beat level (Kimura et al., 2012).

1.4. EFFECT OF DYSFUNCTION OF NEURAL- TARGET INTERACTION
Synaptic transmission depends on the association of the pre- and post-synaptic
elements which are also highly regulated to ensure accuracy in information transfer.
Dysfunction in nerve-target interaction can result in pathological conditions (Chen et al.,
2007; Kimura et al., 2009), including neurodegenerative disorders (Dadon-Nachum et al.,
2011). It has been shown that the programmed cell death that occurs during development
involves synaptic elimination. It has been further suggested that the cells that survive this
period of naturally occurring cell death, do so by competing for target-derived neurotrophic
factors (Oppenheim et al., 2000). It can then be hypothesized that the neuronal dysfunction
or death that occurs in adults can be caused in part, by the deficiency in target-derived
neurotrophic factors.
1.4.1. Effects of dysfunction of motor nerve-skeletal muscle interaction
Motor neurons are the sole means by which the brain can trigger voluntary
(skeletal) muscle to contract and produce all movements that occur in the body. Motor
neuron diseases affect motor neurons in the central and peripheral nervous system. As a
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result, voluntary movements are compromised. There are a number of motor neuron
diseases (reviewed in Wijesekera and Leigh, 2009), which include upper and lower motor
neurons, the motor neurons whose cell bodies are located in the motor cortex and spinal
cord respectively. The pure lower motor neuron diseases include spinal muscular atrophy,
a group of genetic disorders that are caused by a loss of motor neurons in the spinal cord
and the brainstem. Primary lateral sclerosis mostly affects upper motor neurons and causes
stiffness and weakness of the limbs, voice, or swallowing muscles. Amyotrophic lateral
sclerosis (ALS) is a common motor neuron disease that affects both the upper and lower
motor neurons: the cerebral cortex, the brainstem, and the spinal cord (Wijesekera and
Leigh, 2009).
Neuronal cell death is the common feature in neurodegenerative diseases,
including those mentioned above. Several investigators use ALS animal models to examine
how neurodegeneration occurs. The full pathogenesis of ALS is not well understood;
however, several hypotheses have been proposed as key factors for causing neuronal death
in ALS (Wijesekera and Leigh, 2009). The point at which degeneration or death of a motor
neurons starts in ALS has been the center of investigations. The proposed sites for neuronal
death in ALS can be summarized into two major areas, the dying-forward and dying-back
hypotheses.
1.4.1.1. The hypotheses in the dying-forward theory
The dying-forward theory assumes that the pathogenesis is initiated at the soma
and progresses towards the axons or dendrites. This may include genetic causes and
mutations of copper/zinc superoxide dismutase 1 gene (SOD1). Although the SOD1 mutant
accounts for only 20% of all familial ALS cases and only 10% of all ALS cases, the
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discovery of SOD1 mutation has provided insight into how motor neuron dysfunction may
occur. Generally, almost 90% of ALS cases are without genetic linkage and the cause is
unknown (Burvill, 2009; Wijesekera and Leigh, 2009). One of the hypotheses is that failure
in SOD1 causes glutamate excitotoxicity which contributes to the neuronal death. The
physiology behind glutamate toxicity is based on overstimulation of glutamate receptors
by glutamate neurotransmitter (Burvill, 2009). Because the SOD1 gene is also involved in
glutamate reuptake, the mutation in SOD1 results in accumulation of glutamate at the
synapse which causes more damage to neural cells (Orrell, 2010; Shaw, 2005). Another
hypothesis is that the mutant SOD1 plays a part in free radical-mediated oxidative stress,
although the mechanism of action is not fully understood. Barber et al. suggests that the
mutant SOD1 may be toxic through loss of function, inhibition of normal SOD1, or an
increase in mutant SOD1 activity leading to increased hydrogen peroxide and hydroxyl
free radical levels (Barber et al., 2006). Along with oxidative stress, mitochondrial
dysfunction is another proposed factor that may cause neuronal death in a dying forward
manner.
The hypothesis that protein misfolding and aggregation is the major cause of
neuronal death has been of supported by research results. This is because the misfolded
proteins are not only observed in ALS but in other neurodegenerative disorders such as
Parkinson’s and Alzheimer’s diseases (Dunnings et al., 2012; Vekrellis et al., 2011). In
ALS, the mutant SOD1 aggregates with itself and with other proteins (Burvill, 2009). It is
hypothesized that the accumulation of aggregated proteins prevents the neural cells from
carrying out their normal activities and eventually the motor neurons die.
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1.4.1.2. The hypotheses in the dying-back theory
The dying-back theory has attracted the attention of most investigators studying
neurodegeration. Studies have indicated that in early stages of ALS disease, motor nerve
terminals are seen partially degraded while the cell bodies in the spinal cord are mostly
intact (reviewed in Dadon-Nachum et al., 2011). These observations suggest that axon
terminals in ALS degenerate first, followed by progression towards the cell body in the
spinal cord, brain stem, or motor cortex (Fischer et al., 2004). It has also been proposed
that the neuromuscular junction degenerates first and this degeneration may not only
precede, but actively cause the loss of upper and lower motor neurons (Krakora et al.,
2012). This hypothesis can also explain other potential mechanisms involved in the dyingback theory. One such mechanism is the disruption of retrograde axonal transport that is
observed prior to disease manifestation (Krakora et al., 2012; Parkhouse et al., 2008,
Wijesekera and Leigh, 2009). Another major hypothesis in the dying-back theory is the
reduction of target-derived neurotrophic factors that have been observed in ALS patients
and ALS transgenic animals. These small proteins are responsible for neuroprotection and
possess regenerative properties, thus, their deficiencies have been proposed to be involved
in motor neurons death in adults (Brujin et al., 2004; Krakora et al., 2012). However, little
is known about what normally regulates the production of neurotrophic factors by target
tissues.
1.4.1.3. Summary and comments on the neurotrophic factor hypothesis
At this time, there is no exclusive factor that is known to cause motor nerve
degeneration. It is not clear whether the mechanisms outlined above all cause the
neurodegeneration in ALS. It may be possible that the outlined mechanisms are actually
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the results of degeneration itself. Since the dying-back hypothesis assumes that motor
neurons die at the synapse first, while the cell bodies are kept intact, therapies providing
neuroprotection to axons at the distal end may be the most valuable. However, gaps in
knowledge about regulation of neurotrophic factors still exist. These gaps may include
understanding a) Which factors normally regulate secretion and release of a neurotrophic
factor from target tissues? b) Which is the optimal level of activation of a target tissue that
results in maximal production of neurotrophic factor? c) What is the physiological
significance of the differential response of each motor nerve to a neurotrophic factor in the
motor neuron pool? Understanding neurotrophic factor physiology will enhance the
therapeutic intervention for peripheral nervous system disorders.

1.4.2. Dysfunction in cardiac nervous system
As stated earlier, the mammalian heart is extensively innervated by both extrinsic
and intrinsic nerves that compose the cardiac nervous system. The intrinsic ganglia of the
adult mammalian heart contain approximately 43,000 neurons (Pauza et al., 2000). This
local circuit within the heart not only acts as a relay system but gives the heart the intrinsic
ability to independently function without extrinsic neural input (Vasegh and Shivkumar,
2008). However, the rate and rhythm of the heart are under control of the extrinsic nervous
system. Thus, sympathetic or parasympathetic dysfunction may result in cardiac disorders.
1.4.2.1. Effect of altered communication between sympathetic nerves and cardiac muscle
The primary role of the sympathetic nervous system in the heart is to accelerate
the rate and force of contraction of cardiomyocytes. Studies have shown that cardiovascular
diseases may be caused by the dysfunction of sympathetic neurons (Chidsey et al., 1963;
Himura et al., 1993; Meredith et al., 1991). Increased heart rate in pathological heart has
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been associated with sympathetic overactivity, which in turn has been linked with increased
in NE release (Esler, 2011; Kimura et al., 2012). Also, NE administration has been shown
to affect NGF protein expression levels in vivo and in vitro (Esler, 2011; Kimura et al.,
2012). This may indicate that elevated NE release in heart diseases may impact the trophic
effects of NGF on sympathetic neurons. Studies aimed at determining the regulation of NE
in normal and pathological heart may give insight into the relationship between
neurotransmitter effects and neurotrophic factors expression in the heart.

1.4.2.2. Effect of altered communication between parasympathetic nerves and cardiac
muscle
An interesting question may be whether the overactivation of the sympathetic
nervous system in cardiac pathophysiology is a result of failure in the parasympathetic
control. The involvement of parasympathetic innervation in heart failure was tested in early
studies conducted by Eckberg et al. (1971). Parasympathetic effects were blocked with
atropine following adrenergic blockade with propranolol in patients with heart disease and
in normal individuals. Results from these early studies showed that atropine significantly
elevated heart rate in normal subjects compared to individuals with heart disease in which
the effect of atropine was low (Eckberg et al., 1971). In humans, with the chronic heart
failure the degree of parasympathetic dysfunction was found to be related to the severity
of left ventricular dysfunction (Nolan et al., 1992). However, identifying the mechanism
underlying the pathology has been challenging. In dogs with left ventricle dysfunction, but
no heart failure, indices of parasympathetic control decreased significantly after four days
of pacing, whereas, in dogs with fully developed heart failure, both vagal and sympathetic
contributions were small. These observations suggest that changes in vagal control of heart
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rate become apparent at a very early developmental stage of left ventricle dysfunction
(Kinugawa et al., 1995). Thus, it can be further hypothesized that parasympathetic
dysfunction may account for the elevated heart rate.
1.4.2.3. Potential mechanism underlying the decrease in vagal control
Although the mechanism underlying the loss in vagal control is not clear, several
potential mechanisms related to ACh neurotransmitter have been proposed. A decrease in
acetylcholinesterase, the enzyme responsible for ACh breakdown, has been reported in the
sinoatrial node with heart failure, suggesting reduced cholinergic neurotransmission
(Dunlap et al., 2003). Bibvski and Dunlap (2004) suggested that the reduction in the
parasympathetic control in heart failure occurs due to the decrease in presynaptic
transmission in parasympathetic ganglia which is mediated by nicotinic acetylcholine
receptors (nAChRs). Reduced expression of vesicular acetylcholine transporter has been
observed in heart failure (Lara et al., 2010). Recently, it was found that cardiomyocytes
also secrete ACh. This suggests that non-neuronal sources of ACh may be induced to boost
cholinergic signaling to counterbalance sympathetic overactivity (Rana et al., 2010; Roy
et al., 2013). Thus, therapies aimed at parasympathetic neuroprotection such as enhancing
parasympathetic survival and/or activation (Rana et al., 2011), may have positive effects
on patients with cardiac disorders displaying sympathetic overactivation.

1.5. TARGET-DERIVED NEUROTROPHIC FACTORS FOR AUTONOMIC AND
MOTOR NEURONS
As described above, some neurotrophic factors exert their trophic effects in a
synergistic way. When tested as a single neurotrophic factor BDNF, NT-3, or NT-4/5 failed
to rescue granule neurons in the dentate gyrus and the cerebellum, while the combination
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of BDNF and NT-3 rescued the neurons from programmed cell death (Gould and Enomoto,
2009). In the periphery, administration of a combination of BDNF and GDNF has been
shown to enhance motor neuron survival after brachial plexus lesion, while BDNF or
GDNF alone was shown to have no effect (Aszmann et al., 2002). However, in most cases
preferential utilization of a single neurotrophic factor by neuronal subpopulation has been
observed. NGF exclusively has protective effects for cardiac sympathetic neurons (LeviMontalcini et al., 1951), whereas, GDNF is known as a potent neurotrophic factor for
somatic motor neurons (Bohn, 2004; Henderson et al., 1994). Heart-derived GDNF has
been shown to give trophic support to parasympathetic fibers (Enomoto et al., 2002; Hasan,
2013; Rana et al.,2011) and developing sympathetic fibers (Martinelli et al., 2002; Miwa
et al., 2013).
1.5.1. Nerve growth factor
NGF was the first growth factor to be identified in the neurotrophin family.
Subsquently, NGF signaling and function have been studied extensively. The trophic factor
was purified from the submaxillary glands of male mice and used as a survival factor for
neurons in culture (Levi-Montalcini, 1951). NGF was shown to support the growth of
axons of sympathetic and sensory neurons in vivo and in vitro, but had little or no effect
on motor neurons (Albers et al., 1994; Glebova and Ginty, 2004; Levi Montalcini, 1951).
NGF was also shown to play a significant role in the development, differentiation, survival,
and maintenance of both sympathetic and sensory neurons (Levi-Montalcini, 1951, 1987).
In addition to its role as a survival factor, NGF is involved in synaptic transmission.
Lockhart et al. found that application of exogenous NGF in vitro produced a pronounced,
reversible enhancement of synaptic strength, whereby the effect of NGF on synaptic
16

transmission was shown to be concentration-dependent (Lockhart et al., 1997). The broad
range of effects of NGF is summarized in Table 1.
1.5.1.1. Heart-derived NGF and the sympathetic nervous system
A number of studies have shown that NGF is required for cardiac sympathetic
innervation (Glebova and Gity, 2004). Studies have also shown that the levels of NGF
expressed in innervated heart correspond approximately to the density of sympathetic
innervation (Heumann et al., 1984; Shelton and Reichardt, 1984). Overexpression of NGF
in the heart results in hyperinnervation, suggesting that NGF prevents programmed cell
death in cardiac sympathetic neurons (Glebova and Ginty, 2004). The survival effect of
NGF on sympathetic neurons was confirmed in NGF knockout mice. The number of
sympathetic ganglion neurons was significantly reduced in mice lacking genes for NGF or
for its receptor TrkA. Similar results were obtained in mice treated with NGF neutralizing
antibodies (Angeletti and Levi-Montalcini, 1997; Crowley et al., 1994; Govoni et al., 2011;
Snider, 1994). NGF has also been shown to enhance cardiac reinnervation of surgically
denervated canine heart (Kaye et al., 1979), suggesting a strong dependence on NGF for
sympathetic innervation.
1.5.1.2. Challenges with heart-derived NGF
Since its discovery, a number of studies have demonstrated the importance of
NGF in the regulation of sympathetic neuronal development and innervation (LeviMontalcini, 1987; Govoni et al., 2011). However, there are some discrepancies in the
results describing changes in NGF levels in diseased heart. First, some studies have
reported unusual sympathetic nerve sprouting in infarcted hearts, which was correlated
with overexpression of NGF, and was responsible for increased sympathetic effects in heart
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failure. However, other studies have reported the constant reduction of NGF and a decrease
in sympathetic innervation in congestive heart failure (Cao et al., 2000; Chen et al., 2007;
Cohn et al., 1984; Hassankhan et al., 1995; Kaye et al., 2000; Kimura et al., 2007; Oh et
al., 2006). A second challenge is the regulation of NGF levels with NE administration.
While several studies have reported an increase in NGF levels with NE treatment, others
have shown a constant reduction in NGF concentration with NE treatment (Govoni et al.,
2011; Kaye et al., 2000). Similarly, expression of NGF receptor TrkA and its mRNAs
decreased in dogs treated with NE (Govoni et al., 2011; Qin et al., 2002). Third, the
function of NGF synthesized in various glands, including salivary glands, are yet to be
determined (Govoni et al., 2011). These challenges indicate that more studies are needed
to better understand NGF regulation and function in the mature cardiac sympathetic
system.
1.5.2. Glial cell-derived neurotrophic factor
Glial cell line–derived neurotrophic factor was purified from B49 glial cells and
was first identified as a potent survival factor for dopaminergic neurons in the CNS (Lin et
al., 1993). Later, GDNF was reported to be a trophic factor for other populations of neurons
in the peripheral nervous system (PNS) including spinal motor neurons (Bohn, 2004;
Henderson et al., 1994; Kannings et al., 2010), sensory neurons and autonomic neurons
(Buj-Bello et al, 1995; Matrinelli et al., 2002; Enomoto et al., 2000; Hashino et al., 2001).
Like other members of the GDNF family, GDNF induces its trophic effects via GPIanchored GFR-1. The complex of GDNF-GFR-α1-GPI activates autophosphorylation of
the receptor tyrosine kinase, RET, which in turn triggers downstream signaling cascades
including phosphatidylinositol 3-kinase (PI3-kinase), extracellular regulated kinase
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(ERK), and mitogen-activated protein kinase (MAPK: Soler et al., 1999). In the absence
of RET, neural cell adhesion molecule (N-CAM) was reported to be the alternative signal
transducing receptor for GDNF- GFR-1 complex (Paratcha et al 2003; Paratcha and
Ledda, 2008). Like other members of the GDNF family, GDNF is synthesized in a
precursor form, pre-pro-GDNF (Airaksinen and Saarma, 2002). The two mature forms,
GDNF 633 and GDNF 555 are obtained after cleavage during secretion (Springer et al.,
1995; Airaksinen and Saarma, 2002).
The important question is why we should care about GDNF? This trophic factor
is important for many reasons. Specifically, GDNF is a potent survival factor for motor
neurons, so it has the potential to be a therapeutic agent for neurodegenerative diseases
such as Parkinson’s and ALS. The roles played by GDNF in development and maintenance
of the sympathetic and parasympathetic innervation of the heart could allow GDNF to be
used to counteract an overstimulated cardiac sympathetic system by increasing
parasympathetic effects. Moreover, GDNF has a broad range of mechanisms of action,
plays a major role in synaptic plasticity and acts indirectly by interacting with serval other
pre-and postsynaptic molecules to exert trophic effects. Therefore, it is clearly possible that
other, currently unidentified roles for GDNF exist which could lead to more therapeutic
applications.
1.5.2.1. GDNF is a potent survival factor for motor neurons.
Although GDNF was first discovered as a potent survival factor for
dopaminergic neurons (Lin et al., 1993) and later as a survival factor for other neuronal
populations (Buj-Bello et al., 1995), it has also been shown to be a potent survival factor
for motor neurons during development and in adulthood (Bohn, 2004; also reviewed in
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Vianney et al., 2013). When compared with other neurotrophic factors, GDNF was found
to be more potent in preventing programmed cell death in cultured motor neurons. GDNF
prevents the death of nearly 100% of motor nerves in neonatal rats that have been deprived
contact with their targets. (Henderson et al., 1994; Yan et al., 1995; Houenou et al., 1996).
In addition, there was a significant loss of motor neurons in GDNF knockout mice (Moore
et al., 1996). It was also reported that the survival of motor neurons during programmed
cell death depends on GDNF secreted by skeletal muscle (Angka et al., 2008). These results
indicated that GDNF secreted by skeletal muscle is sufficient to provide a survival effect
to the motor nerve innervating muscle during development; however recent studies have
shown that within motor neuron pools, gamma and alpha-motor neurons are dependent on
the trophic effects of GDNF (Gould and Enomoto, 2009; Kannings et al., 2010; Shneider
et al., 2009). Nerve injury studies have also revealed the trophic importance of GDNF to
motor neurons in adults. GDNF has been regarded as a potential therapy for spinal cord
injury (Cote et al., 2011, also reviewed in Vianney et al., 2013). From this, it can be
suggested that motor neurons depend on GDNF as a trophic factor and that GDNF may be
useful as a potential therapeutic candidate for motor neuron diseases, including ALS,
Parkinson’s disease, and following spinal cord injury.
1.5.2.2. GDNF in the heart
In the heart, the preferential utilization of neurotrophic factors by sympathetic
and parasympathetic systems has been suggested. While NGF has been shown to be mainly
associated with sympathetic fibers (Heumann et al., 1984; Habecker et al., 2008), two of
the GDNF family members, GDNF and neurturin (NRTN), were shown to be mainly
associated with the parasympathetic system (Hiltunen et al., 2000; Hiltunen and
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Airaksinen, 2004; Hoover et al., 2004; Mabe and Hoover, 2006, 2009). Enomoto and coinvestigators found that both GDNF and NRTN are required for cranial parasympathetic
ganglia development. Interestingly, the two closely related trophic factors differ in terms
of the time at which they exert their trophic effects. While GDNF was found to be critical
for early cellular proliferation and migration, NRTN exerts its effect later and is required
for further development and maintenance of these neurons. This switch in ligands may
correspond to a switch in availability of receptors. While GDNF receptor (GFR-1) is
predominant in early stages, NRTN receptor (GFR2) dominates after ganglion formation
(Enomoto et al., 2000). Interestingly, unlike NRTN which is mainly associated with
parasympathetic fibers, GDNF provides the trophic effect in both sympathetic and
parasympathetic fibers in the heart. GDNF was shown to be required for the survival of
sympathetic neurons (Martinelli et al., 2002). It is maximally expressed during embryonic
stage and is critical for sympathetic innervation of neonatal heart rats (Miwa et al., 2010).
The same authors also found that GDNF provided a greater degree of support for
sympathetic neurite growth and cardiac innervation than NGF (Miwa et al., 2013). These
reports suggest that GDNF is also critical for the development and innervation of the heart
and possibly for reinnervation after myocardial injury. A better understanding of processes
regulating GDNF expression in the heart may help to understand the potential roles of
GDNF in development of sympathetic and parasympathetic nervous system in healthy,
diseased, or aging heart.
1.5.2.3. GDNF: a therapeutic candidate for neurodegeneration
Most current treatments for neurodegenerative diseases are focused on altering
neurotransmitters expression or effects. Such treatments target increasing dopamine in
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Parkinson’s disease (Poewe et al., 2010), suppressing glutamate in ALS (Burvill, 2009), or
blocking norepinephrine action in heart disease (Aggarwal et al., 2001; Liang et al., 2003).
However, these pharmacological agents do not prevent continued neurodegeneration or
neural dysfunction. Therefore, treatment with neurotrophic factors is a promising therapy
for nerve restoration. In particular, GDNF is regarded as therapeutic candidate for
neurodegenative motor neuron diseases. Treatments using direct neurotrophic delivery into
target sites have been developed and clinical trials are underway. Methods of GDNF
delivery include, but are not limited to, biodegradable microspheres (Gabayo et al., 2009),
gene therapy (Fletcher et al., 2011), stem cell therapy (Pastor et al., 2012), and GDNFLiposome complex technique (Wu et al., 2014). Although results from these studies have
been promising, there are some accompanying challenges discussed in Kannings et al.,
(2010).
Interestingly, other treatments or mechanisms that have been utilized or
suggested for neuroprotection have been shown to indirectly act through GDNF. Riluzole,
currently the only drug approved for ALS treatments, was shown to increase GDNF
production, even though its mechanism of action was designed to suppress the action of
glutamate neurotransmitter (Burvill, 2009). The anti-dementia drug, FK960 [N-(4-acetyl1piperazinyl)-p-fluorobenzamide monohydrate] also upregulates GDNF expression in
spite of the fact that the drug was originally identified as a cholinergic agonist (Koyama et
al., 2004; Matsuoka and Aigner, 1997). Furthermore, studies including those in our
laboratory have shown that exercise training elevates muscle-derived GDNF protein in rat
and mouse models (Cote et al., 2011; Gyorkos et al., 2014; McCullough et al., 2011;
Wehrwein et al., 2002). These observations may help explain why neurotrophic factors
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could be some of the best therapeutic agents for maintaining and restoring dysfunctional
nerves.
1.5.2.4. GDNF potential mechanisms of Action: GDNF acts on synaptic plasticity
Administration of GDNF causes axonal growth (Wang et al., 2002) and the
number of axons innervating skeletal muscle depends on the concentration of GDNF
protein available (Nguyen et al., 1998). Overexpression of GDNF causes hyperinnervation
in muscle fibers (Keller-Peck et al., 2001; Zwick et al., 2001), suggesting that GDNF
prevents motor neurons from undergoing apoptosis. GDNF acts on both presynaptic and
postsynaptic components during synaptic transmission increases both spontaneous and
evoked neurotransmitter release (Ribchester et al., 1998; Wang et al., 2001). Changes in
endplate morphology following exercise correlate with an increase in GDNF at the NMJ
(McCullough et al., 2011; Gyorkos et al., 2014). These results suggest that GDNF likely
plays a role in synaptic maintenance and remodeling at the NMJ.
1.5.2.5. GDNF potential mechanisms of action: Interaction with targets at NMJ
GDNF interacts or synergizes with other molecules at the soma, pre-synaptic,
and post-synaptic levels to induce its trophic effect. In the cell body, muscle-derived GDNF
increases neuregulins (NRG), an isoform of acetylcholine receptor-induced activity
(ARIA). Neuregulins are expressed in motor neurons and are anterogradely transported to
the NMJ where they increase the expression of acetylcholine receptors (AChRs: Loeb and
Fischbach, 1997). Muscle-derived GDNF also controls cell body positioning, dendrite
patterning, assembly of sensory-motor reflex circuitry, and muscle innervation, by
triggering the expression of ETS (E26 transformation-specific) transcription factor Pea3 in
the spinal cord (Haase et al., 2002; Vrieseling and Arber, 2006). GDNF interacts with the
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neural adhesion molecule (NCAM 140 isoform) in stimulating neurite outgrowth in both,
central and peripheral nervous system (Paratcha et al., 2003; Paratcha and Ledda, 2008).
GDNF also mediates axon-glial interaction by inducing proliferation of Schwann cells
(Allodi et al., 2012). Of all neurotrophic factors tested, only GDNF specifically enhances
expression of frequenin, an N-type calcium binding protein, thereby facilitating calcium
influx into the presynaptic nerve terminal (Wang et al., 2001). Unlike NT-3/4, targetderived GDNF regulates NMJ transmission by stimulating expression of
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conductance Ca2+ activated K+ channels (KCa2+) in developing chick lumbar motoneurons
(Martin-Caraballo and Dryer, 2002). In the postsynaptic cell, GDNF was shown to
increase the size of AChR aggregates (Wang et al., 2002) and cause insertion of ACh
receptors (Yang and Nelson, 2004). Taken together, it can be suggested that GDNF
promotes axon branching and innervation, enhances synaptic formation, maintains
synaptic connection, and modulates mammalian NMJ directly and indirectly through
interactions with molecules of both presynaptic and postsynaptic structures.
1.5.2.6. GDNF potential mechanisms of GDNF action: Synthesis and transport modes
GDNF is widely distributed in various tissues of the central and peripheral
nervous system, suggesting the importance of its neuroprotective trophic effect.
Surprisingly, the synthesized and released GDNF is transported in different ways. Table 1
briefly summarizes the cells and tissues that have been confirmed to express GDNF. In
addition to being secreted in various tissues within and outside the nervous system, GDNF
reaches its target in variety of ways, including retrograde and anterograde transport and
paracrine or autocrine modes of action on tissues. GDNF was shown to be transported via
axons to cell bodies through a receptor-mediated process, in a retrograde fashion (Nguyen
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et al., 1998; Rind et al., 2005; Vrieseling and Arber, 2006). Zhao et al. showed that GDNF
is secreted by astrocytes of the CNS and provides its effects on peripheral nervous system
by anterograde transport (Zhao et al., 2004). In the paracrine mode of action, musclederived GDNF induces the Schwann cell proliferation at the NMJ (Allodi et al., 2012).
GDNF increases AChR density in the absence of innervation, indicating an autocrine
action, since both the ligand and its receptor are expressed in skeletal muscle (Yang and
Nelson, 2004; Vianney and Spitsbergen unpublished data). Results of a study conducted
by Li et al. (2007), using both myoGDNF mice and GFAP-GDNF mice, showed that the
classical retrograde transport may have more physiological effects for treatment of
amyotropic lateral sclerosis (ALS) compared to anterograde transport. Due to the
widespread expression in different regions of the body and the various modes of action,
GDNF has been shown to be a very important molecule that performs multiple functions
to support cellular function and survival.

1.6. AIM OF STUDY
The broad goal of this study is to examine factors that normally regulate GDNF
expression in skeletal muscle and cardiac muscle, with an emphasis on comparing the
similarities and differences in these voluntary and involuntary muscles. Previous studies
with nerve-muscle co-culture in our laboratory have shown that GDNF protein levels are
reduced when skeletal muscle is in contact with cholinergic nerves (Vianney and
Spitsbergen, 2011). The hypothesis being tested is that cellular activation by neural cells,
via neurotransmitter release, regulates GDNF expression in voluntary and involuntary
muscles. Although the survival effect of exogenous GDNF on neurons has been extensively
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investigated (Henderson et al., 1994; Keller-Peck et al., 2001; Angka et al., 2008;
Dudanova et al., 2010), little is known concerning the normal regulation of expression in
muscle-derived GDNF. Understanding the normal factors that regulate GDNF expression
in voluntary and involuntary muscles will provide a better understanding of how these
processes may be modulated therapeutically.
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CHAPTER 2
EXPERIMENTAL DESIGN, MATERIALS, AND METHODS
A: EXPERIMENTAL DESIGN - RATIONALE AND DEVELOPMENT

2. 1. SPECIFIC AIMS

The broad goal of this study was to examine factors that normally regulate glial cell
line-derived neurotrophic factor (GDNF) expression in skeletal and cardiac muscles, with
an emphasis on comparing the similarities and differences in these voluntary and
involuntary muscles in relation to GDNF production. The hypothesis tested was that
cellular activation by neural cells, via neurotransmitter release, regulates GDNF expression
in voluntary and involuntary muscles. This hypothesis was addressed in the following
specific aims:

2.1.1. Specific Aim #1
The regulation of expression of GDNF is different in voluntary and involuntary
muscles: Studies under this aim characterized GDNF synthesis and secretion in skeletal
muscle and cardiac muscle and examined the similarities and differences in production of
GDNF in these voluntary and involuntary muscles. GDNF protein content in the muscle
was analyzed by enzyme-linked immunosorbant assay (ELISA), immunocytochemical
techniques, and western blot. Since nerve growth factor (NGF) is a major trophic factor for
the autonomic nervous system, the same procedure was performed with NGF to compare
its synthesis and secretion with that of GDNF in cardiac muscles. Results from these studies
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confirmed the presence and examined the patterns of production of the growth factors at
the cellular level.

2.1.2. Specific Aim # 2
Neurotransmitters found in somatic motor neurons, sympathetic neurons, or
parasympathetic neurons are involved in regulation of GDNF production by skeletal
and cardiac muscle: Studies under this aim were focused on understanding the cellular
processes controlling GDNF production at the level of the cell. The hypothesis tested was
that neural cells innervating muscle regulate GDNF expression via neurotransmitter
release. The study examined the presence, distribution, and localization of neurotransmitter
receptors on differentiated skeletal muscle using immunocytochemical methods.
Specificity of effects of a neurotransmitter on GDNF secretion was examined by studying
effects of specific blocking agents. Results from this study determined that
neurotransmitter-receptor interactions are involved in regulating GDNF production by
muscle cells.

2.1.3. Specific Aim #3
Direct electrical stimulation affects GDNF expression in skeletal muscle and
cardiac muscle: Studies under this aim examined the effect of direct electrical stimulation
on GDNF secretion by skeletal muscle and cardiac muscle. The hypothesis was that there
is a relationship between muscle contraction and GDNF production in both voluntary and
involuntary muscles. Various frequencies and durations of stimulation were examined to
determine the optimal stimulation pattern for eliciting changes in GDNF levels. The study
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also aimed to give insight into potential benefits of the use of electrical stimulation on
motor and autonomic nervous systems in regards to enhancing the trophic effect of GDNF.

2.2. INNOVATIONS
2.2.1. Idea/Hypothesis
This study examines whether neural cells regulate their own supply of GDNF
produced by voluntary and involuntary muscle cells. As mentioned earlier, there are a
number of studies examining the effects of exogenous GDNF on neurons and target tissues
(Henderson et al., 1994; Houenou et al., 1996; Nguyen et al., 1998; Keller-Peck et al.,
2001; Wang et al., 2002; Angka et al., 2008; Dudanova et al., 2010); however, to our
knowledge there are no studies examining and comparing how GDNF production is
normally regulated at the cellular level in skeletal and cardiac muscle. Thus, we believe
that the results from these studies are the first to report that GDNF production is
differentially regulated in voluntary and involuntary muscles and the nervous system may
be involved in the regulation process.

2.2.2. Materials
This research involves the use of a novel cell line (HL-1) derived from mouse atrial
cells. HL-1 cells retain ultrastructural characteristics of adult atrial cardiac cells, including
the ability to contract spontaneously in culture (Claycomb, 1998). To our knowledge this
study is the first to evaluate GDNF production in HL-1 cells. Thus, results from this study
suggest that HL-1 cells are a viable model for studying the synthesis and secretion of
GDNF in the heart.
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2.2.3. Methods
These studies use an electrical stimulation apparatus that maintains a controlled
environment for cultured cells; this includes placing cells in a standard cell incubator for
long-term stimulation. This method diverges from Marotta et al., (2004) by utilizing a
custom-made interface box instead of using two cards that are placed adjacent to the short
axis of a 6-well plate. Within the interface box a unity gain voltage buffer maintained the
shape of the voltage pulse while providing current to up to six electrodes. Also, stainless
steel electrodes are used instead of platinum electrodes.

2.3. PRELIMINARY STUDIES
The following section describes the preliminary studies that were performed using
these cell lines. Material and methods involved in the preliminary studies are briefly
explained as the full description of methods is found in the material and methods section.

2.3.1. Do C2C12 skeletal muscle cells or HL-1 cardiac muscle cells express GDNF?
Previous studies have shown target tissues of the peripheral nervous system,
including skeletal and cardiac muscle, express GDNF (Suzuki et al., 1998; Martinelli et al.,
2002). However, the regulation of GDNF production in these various tissues is still to be
determined. To address the question whether these voluntary and involuntary cell lines
(C2C12 and HL-1, respectively), express GDNF, cells were grown according to the
protocol for each cell type. Localization of GDNF and myosin proteins were examined by
immunocytochemical techniques. GDNF content in cell and levels of secretion were
evaluated using ELISA. Results from these preliminary studies served as part of specific

55

aim one. Figure 2.1 shows that GDNF could be detected in both types of cells. Unlike
skeletal myotube, GDNF in cardiac muscle cells seems to be concentrated in the nucleus.

GDNF in skeletal and cardiac muscles cells

I: Red = myosin

II: Green = GDNF

III: Overlay

Figure 2.1. Localization of GDNF and myosin in skeletal and cardiac muscle cells.
Skeletal and cardiac muscle cells were fixed with paraformaldehyde. A. C2C12 myotubes
and B. HL-1 cardiac muscle cells. For both cell types: Panel I, cells were immunolabeled
with mouse anti-myosin (sarcomeric myosin MF-20 for cardiac), followed by secondary
antibody conjugated with Alexa Fluor 568 (red). Panel II, rabbit anti-GDNF followed by
secondary antibody conjugated with Alex Fluor 488 (green). Panel III, overlay. Images
were captured using a laser scanning confocal microscope.
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Figure 2.2 below shows that the amount of GDNF secreted by cardiac muscle cells
was higher than that secreted by skeletal muscle cells. This observation suggests that
GDNF secretion processing in these types of muscle cells may differ.

Comparison of GDNF secretion content in skeletal and cardiac muscle cells
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Figure 2.2. GDNF secretion levels in skeletal and cardiac muscle cells. Cells were
grown and allowed to differentiate. Samples were collected from 5-day-old cardiac muscle
cells and 7-day-old myotubes. Cardiac muscle cells secrete more GDNF than skeletal
muscle myotubes. GDNF protein concentration was determined by ELISA. Values are
presented as mean ± S.E.M. and Asterisk (*) indicates significance (P ≤ 0.05). N = 8.
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2.3.2. Are somatic motor neurons involved in regulation of GDNF production by
skeletal muscle?
The goal in this study was to determine whether neural cells are involved in
regulation of GDNF production in the target tissues. Other studies have shown that the
survival of peripheral neurons depends on neurotrophic factors supplied by peripheral
target tissues (Hassankhani et al., 1995; Martinelli et al., 2002, Nosrat et al., 1996). GDNF
is now known as a neurotrophic factor for motor neurons (Henderson et al., 1994), which
is secreted by skeletal muscle (Angka et al., 2008; Lie and Weis, 1998) and provides trophic
support to the spinal motor neurons via a retrograde mode of action (Nguyen et al., 1998).
If this is the case, it can be assumed that a strong relationship should exist between the
nerve and its target in regulating the levels of a neurotrophic factor needed for survival and
maintenance by the nerve. If this hypothesis were true, then the neurons innervating target
tissue should be involved in regulating GDNF production. To test this hypothesis, our
laboratory conducted in vitro studies (Vianney and Spitsbergen, 2011), aimed at creating
neuromuscular junctions in culture. To do this, co-culture studies using skeletal muscle and
neural cells were initiated (Fig. 2.3A). It was observed that differentiated neural cells, do
not contain detectable levels of GDNF protein (data not shown). Figure 2.3B shows
western blot analysis confirming that differentiated NG108-15 do not produce GDNF.
Surprisingly, when neural cells and skeletal myotubes were grown together in the nervemuscle co-culture system, GDNF was localized in both the neural cells and the skeletal
muscle myotubes (Fig. 2.4A-C). Moreover, GDNF protein content was significantly
reduced in nerve-muscle co-cultures compared to skeletal myotubes grown alone (Fig. 2.5).
These results raised the question of how neural cells might be regulating GDNF production.
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This question is addressed as specific aim two, and was examined in chapters three and
four.

Nerve-muscle in culture

B

A

Figure 2.3. Nerve-muscle co-culture system and GDNF molecular sizes. NG108-15
neural cells were added to 7-day-old myotubes and were maintained for 24-36 h to allow
neuromuscular contact to form. Panel A shows a nerve-muscle connection. Panel B shows
western blot results, GDNF protein was found in C2C12 myotubes but not in NG108-15
cells. Lane 1 and 2, GDNF secreted by myotubes in culture medium and Lane 3 and 4,
intracellular GDNF. No GDNF protein was found in culture medium (Lane 5 and 6) or in
cells (Lane 7 and 8) from NG108-15 culture.
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GDNF localization

A

B

Myosin

GDNF

C

D

Overlay

Figure 2.4. GDNF localization in nerve-muscle co-culture system. A-C. Co-cultures of
C2C12 cells and NG108-15 cells were cultured on coverslips in DMEM supplemented by
10% horse serum. The cells were fixed in 4% paraformaldehyde and mouse anti-myosin
followed by donkey anti-mouse conjugated to Alexa Fluor 568 was added to localize
myosin. Also, rabbit anti-GDNF followed by donkey anti-rabbit conjugated to Alexa Fluor
488 was added to localize GDNF. A. Myosin (red), B. GDNF (green), and C. Overlay, and
D. Negative control. GDNF was observed in both NG108-15 cells and myotubes. All
images were captured by Zeiss laser scanning confocal microscope.
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Measurement of GDNF protein concentration by ELISA
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Figure 2.5. Quantification of GDNF protein secretion in nerve-muscle co-culture.
Nerve-muscle co-cultures were grown as in previous studies. ELISA results show that
GDNF secretion is inhibited in nerve-muscle co-culture (= treatments). Values are
presented as Mean ± S.E.M. Asterisk (*) indicates significance from control, (P ≤ 0. 05),
N = 4.
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2.3.3. Does electrical stimulation affect GDNF production by skeletal muscle cells?
Electrical stimulation has been shown to induce muscle contraction and protein
sysnthesis (Donnelly et al., 2010). Preliminary studies on electrically stimulated cells were
initiated in our laboratory to test whether electrical impulses affect GDNF production in
C2C12 myotubes. Cells were stimulated at the frequency of 1Hz for 90min as previously
decribed in Marrota et al. (2004). Cells were also stimulated at the same frequency for
30min as short-term duration so as to compare with the 90min stimulation. The results
showed that intracellular levels of GDNF produced and GDNF that were secreted both
were significantly reduced when cells were stimulated at 1Hz for 30 and 90 minutes (Fig.
2.6A-B). However, there was a significant difference between GDNF secreted when cells
were stimulated for 90min with that stimulated for 30min. The inhibitory effect seemed to
be reduced at 90min stimulation (Fig. 2.6A), but no difference in GDNF protein levels with
intracellular GDNF (Fig. 2.6B).
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Effect of electrical stimulation on GDNF production in skeletal muscle cells
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Figure 2.6. GDNF production in electrically stimulated myotubes. Day 7 or 8 skeletal
myotubes were stimulated at 1Hz for 30 or 90min. A & B, GDNF production is inhibited.
However, the inhibitory effect is reduced on GDNF secretion with a 90min stimulation, A.
but no effect was observed in intracellular GDNF, B. Values are presented as Mean ±
S.E.M. Asterisk (*) indicates significance from control and ($) indicates significance
between the groups, (P ≤ 0. 05), N = 6.
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2.3.4. Does electrical stimulation alter myosin heavy chain in C2C12 myotubes?
Since electrical stimulation can induce phenotypic changes in myotubes resulting
in changes to myosin heavy chain from fast to slow myosin (Bayol et al., 2005), we tested
whether stimulation cells at 1Hz could induce a visible change in myosin. The question
was whether the changes in GDNF production that were observed could possibly be
accompanied by changes in myosin expression. However, results from western blot
analysis (Fig. 2.7A-B) and immunocytochemistry (Fig. 2.8A-B) did not show significant
differences in the amount of slow myosin versus fast myosin between controls and
electrical stimulated groups.

Fast and slow myosin in myotubes

B

A

Fast myosin

Slow myosin

Figure 2.7. Fast and slow myosin in electrically stimulated C2C12 myotubes.
Myotubes were stimulated at 1Hz for 30min or 48 hours. Westen blot analys show that fast
myosin (A) and slow myosin (B) do not seem to change with 1Hz electrical stimulation.
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Fast and slow myosin in myotubes
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Figure 2.8. Localization of fast and slow myosin in C2C12 myotubes. Cells were fixed
in 4% paraformaldehyde and mouse anti-slow myosin followed by donkey anti-mouse
conjugated to Alexa Fluor 568 was added to localize slow myosin. Also, rabbit anti-fast
myosin followed by donkey anti-rabbit conjugated to Alexa Fluor 488 was added to
localize fast myosin. For both A and B, slow myosin (I), fast myosin (II), overlay (III). The
results show that fast and slow myosin do not seem to change electrical stimulation. All
images were captured by Zeiss laser scanning confocal microscope.
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With a significant decrease in GDNF following 30 minutes of electrical stimulation,
next we examined whether GDNF receptors (GFR-1) on myotubes are affected by this
short-term electrical stimulation. Western blot results did not show significant differences
in concentrations of GFR-1 between control group and electrically stimulated myotubes.

GDNF receptors on myotubes
Figure 2.9. GFRα-1 receptors

1

2

3

4

5

on C2C12 myotubes. Myotubes
were stimulated at 1Hz for 30
minutes. Lane 1&2: controls
Lanes 3 & 4: Stimulated Lane 5:
protein ladder.

Preliminary results suggest that neural cells utilize GDNF secreted by skeletal
muscle and inhibit further secretion of GDNF by skeletal muscle (Vianney and
Spitsbergen, 2011). Early studies by others have also shown increased GDNF levels in
denervated muscle compared to the muscle with normal innervation (Lie and Weis, 1998).
This suggests that innervation status may be one determinant of GDNF levels secreted by
a target tissue; which in turn, may suggest that the neural cells regulate their own supply
of neurotrophic factors. Studies described in Chapters 3 and 4 utilized the treatment with
neurotransmitters known to be released by motor neurons, sympathetic neurons, and
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parasympathetic neurons, to test the hypothesis that neural cells regulate GDNF production
by skeletal muscle and cardiac muscle via neurotransmitter release. For these studies,
skeletal muscle cells and cardiac muscle cells were treated with acetylcholine (ACh) and/or
norepinephrine (NE). Neurotransmitter receptor blocking agents were also utilized to help
determine which type of receptors were being activated.
In other studies, cells were electrically stimulated to test the hypothesis that
electrical activity is an important regulator of GDNF production.

B. MATERIALS AND METHODS
2.4. MATERIALS
2.4.1. C2C12 skeletal muscle cell line
C2C12 is a mouse myoblast cell line. The cells were originally obtained through
serial passage of myoblasts cultured from the crush injury thigh muscle of 2- month-old
normal mouse of C3H strain. These cells are capable of differentiation into skeletal muscle
myotubes (Yaffe and Saxel, 1977). C2C12 cells have been a useful model for studying
skeletal muscle biology and physiology. This includes processes involved in the
differentiation of myoblasts (Yaffe and Saxel, 1977) and the regulation of apoptosis in
myoblasts (Schöneich et al., 2014). C2C12 cells are also used to study myogenesis
(Burattini et al., 2004), metabolism (Marotta et al., 2004), muscle diseases (Yaffe and
Saxel., 1977), and diabetes (Dymkowska et al., 2014). This skeletal muscle cell line
resembles its in vivo counterparts by expressing proteins that are found in mammalian
skeletal muscle (Burattini et al., 2004; Thelen et al., 1997). The cells express extracellular
matrix proteins (Park et al., 2008), contractile proteins including actin and myosin
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(Burattini et al., 2004), ion channels (Dymkowska et al., 2014), muscle receptors, and
enzymes including acetylcholinesterase (Siow et al., 2002; Vianney and Spitsbergen,
2014). C2C12 cells have also been used in electrical stimulation studies for calcium
imaging (Ishibashi et al., 2009) and exercise induced-glucose uptake (Marotta et al., 2004;
Nedachi et al., 2008). In the current study, C2C12 cells were used to study production of
the neurotrophic factor GDNF and possible regulation by electrical activities or
neurotransmitters.
2.4.2. HL-1 cardiac muscle cell line
HL-1 cells were derived from mouse atria. The cells retain ultrastructural
characteristics in vitro of adult atrial cells, including the ability to contract spontaneously
in culture (Claycomb, 1998). A number of investigators have utilized HL-1 cells for
studying various aspects of cardiac muscle physiology, including apoptosis (Carlson et al.,
2002), cell cycle (Zandstra et al., 2003), electrophysiology (Claycomb et al., 1998),
oxidative stress (Kitta et al., 2001), signal transduction (Chaudary et al., 2002),
transcriptional regulation (Kitta et al., 2001), and cellular transplantation (Watanabe et al.,
1998). In this study we have utilized HL-1 cells to examine regulation of expression of
GDNF and NGF by electrical activity and autonomic neurotransmitters.

2.5. METHODS

2.5.1. Cell culture
Mouse skeletal muscle cells (C2C12), glioma×neuroblastoma hybrid cells (NG10815), and culture medium were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). Culturing procedures were performed according to the ATCC
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protocols. C2C12 myoblasts, undifferentiated skeletal muscle cells, were initially seeded
on a 100-mm plate (Falcon) and maintained in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% fetal bovine serum (Mediatech, Manassas, VA) and 1%
antibiotic–antimycotic (Invitrogen-GIBCO). Cells were incubated at 37 °C in a watersaturated atmosphere of 95% air and 5% CO2. The myoblasts were subcultured (transferred
to new plates) after 2 days. Differentiation of myoblasts to myotubes was induced by
replacing the growth medium with DMEM supplemented with 10% horse serum and 1%
antibiotic–antimycotic. The medium was renewed every 1 to 2 days.
For nerve-muscle co-culture, NG108-15 cells were first cultured on 100-mm
culture dishes in DMEM supplemented with 10% fetal bovine serum, 2% HAT
supplement, a mixture of hypoxanthine, aminopterin, and thymidine (Invitrogen-GIBCO),
and 1% antibiotic–antimyocotic. Differentiation of NG108-15 cells was enhanced by
switching from regular medium to a serum free medium. The medium was renewed every
2 to 3 days. Nerve–muscle co-culture procedure was performed as it was first described by
Chen et al. (2005) and Ling et al. (2005). Briefly, myoblasts were induced to differentiate
and fuse into myotubes. Approximately 1.0×105 NG108-15 cells were plated onto 10-dayold myotube cultures. Co-cultured cells were maintained at 37 °C in a water-saturated
atmosphere of 95% air and 5% CO2.
HL-1cells were cultured using the procedure of Dr. William Claycomb (Claycomb
et al. 1998; White et al. 2004). Cells were initially grown in 100 mm culture dishes for 2
to 3 days, then were transferred to 6-well plates for electrical stimulation or 12-well plates
for treatment with neurotransmitters.
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2.5.2. Treatment with cholinergic and adrenergic agonists and antagonists
All studies in myotubes were performed on 6 or 7 day- old- myotubes. On the day
of experiment, old medium was removed and fresh medium containing 0.1 - 100µM
acetylcholine (ACh) was added. Treatments of HL-1 cells were performed on day 4- or 5day-old cells. ACh (0.1µM, 1µM and 100µM) or norepinephrine (NE: 0.1mM and 1mM)
were added. Conditioned culture medium and harvested cell samples were taken between
0 and 24 hours following treatment. Control plates were processed in the same manner
except that no treatments were made.
Treatments with antagonists: On the day of the experiment, old medium was
removed and cells were treated with fresh medium containing 200nM unlabeled alphabungarotoxin (-BTX: Biotium, CA) for 25 min. Following incubation the culture medium
containing blocking agents was removed and fresh medium containing (0.1µ -100µM)
ACh was added. Samples were collected at intervals of 0h, 30min, 2h, 4h, and 24 h. The
same procedure was performed for cardiac cells except 0.1µM-3µM atropine or
propranolol concentrations (Sigma Aldrich) were used for blocking muscarinic ACh
recptors (mAChRs) and -adrenergic receptors, respectively (Chaote and Feldman, 2003;
Wang et al., 2001). Control plates included: non-treated plates, plates treated with ACh
only, and plates treated with blocking agents only.

2.5.3. Electrical stimulation
The overall approach of Marotta et al. (2004) inspired the electrical stimulation
apparatus outlined in Figure 2.10A. This included its use of switched semicircular
electrodes as part of a culture dish lid, a capacitor to block direct currents, and current
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sampling resistors. Following Donnelly et. al., (2010) stainless steel electrodes were used
instead of platinum electrodes. These electrodes were formed from 19 gauge stainless steel
wire (ACE Hardware #5037023). Electrodes were secured to the 6-well culture dish lid
with bolts which also provided convenient wire connection points using wires with spade
lugs. A Grass Technologies S88 stimulator provided voltage pulses to a custom made
interface box (Figure 2.10 B-C). Within the interface box a unity gain voltage buffer
maintained the shape of voltage pulses while providing current to up to six electrodes. The
voltage buffer used Texas Instruments OPA544 High-Voltage High-Current Operational
Amplifier with unity feedback (Franco, 2002) powered by a Tektronix PS280 power supply
set to +/-29V. Switches SW1-SW6 enabled each pair of electrodes to be individually
selected. Capacitor C1 blocked direct current to reduce medium electrolysis and electrode
oxidation (Donnelly et al., 2010). The voltage across each electrode was available at
banana plug jacks (e.g. A1 and B1, Figure 2.9A) and measurable using two oscilloscope
channels in differential voltage mode. The current through each electrode pair could be
measured using a single oscilloscope channel connected across the corresponding current
sampling resistor R1-6 (e.g. banana jack B1, Figure 2.9A). This required scaling the
voltage waveform by the inverse resistance value. Resistors R1-6 was set to approximately
100Ω. Electrical safety precautions were observed including use of components with
sufficient voltage and power ratings. Fuses limited power supply and electrode currents.
The PS280 power supply current limit feature was also used as a safety precaution.
Three wells were stimulated simultaneously using these apparatus, whereas the
other three wells served as controls. Cells were stimulated at approximately 1Hz or 5Hz
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with an approximate 24V 30ms pulse for 30min – 48hours. All cultures were maintained
at 37°C in water-saturated incubator of 95% air and 5% CO2 during stimulation periods.

A

C

B

Figure 2.10. Electrical stimulation instruments. A. Electrical stimulation apparatus
block diagram. Overall approach inspired by Marotta et al. (2004). Use of stainless steel
electrodes based on Donnelly et al. (2010). B. Pulses were generated by a Grass S88
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stimulator and applied via a custom-made voltage buffer circuit. The buffer circuit was
capacitively coupled to the electrodes to reduce electrolysis. The myotubes were stimulated
directly using stainless steel wire electrodes. The electrodes were bent into half circles and
were integrated into a lid of a 6-well plate as shown in C. In all electrical stimulation
studies, three wells were stimulated simultaneously, whereas the other three wells served
as controls. Cells were stimulated at 1Hz or 5Hz with an approximate 24V 30ms pulse for
30min or 90min. All cultures were maintained at 37°C in water-saturated incubator of 95%
air and 5% CO2 during stimulation period.

2.5.4. GDNF protein isolation
At the completion of each experiment, samples of conditioned medium and cells
were collected. The time interval for sampling ranged between 0h (right after
experimentation) to 24hours. Cardiac cell samples were collected at day 5, whereas skeletal
myotube samples were collected at day 6, 7, 8, or 14 depending on the type of experiment
immunocytochemistry, chemical or electrical stimulation, or co-culture studies,
respectively. For each experiment, a 1-ml sample of culture medium was collected from
each culture dish. To remove cells on dishes, culture medium was removed followed by
washing with calcium/magnesium-free saline buffer. Then, 1ml of sample buffer (a mixture
of phosphate buffered saline, 0.005% Tween-20, 0.5% bovine serum albumin, 0.1 mM
benzethonium chloride, 2mM benzemidine, 0.4 M NaCl, 2 mM EDTA and 164 μl/100 ml
aprotinin) was added to each culture dish containing cells. The cells were scraped from the
dish using a cell lifter (Costar®, Corning Inc., NY). Cells were spun in a cold centrifuge at
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13.5 x g and supernatant was removed and stored. All collected samples were stored at −20
°C until GDNF protein content was measured by enzyme-linked immunosorbent assay
(ELISA) or GDNF protein molecular weights were measured by western blot analysis.

2.5.5. Enzyme-linked immunosorbant assay
GDNF primary antibody (1 µg/ml: R& D Systems) was added to 96-well ELISA
plates, and then incubated overnight at room temperature. Plates were blocked with
Phosphate Buffer Saline (PBS) containing 1% Bovine Serum Albumin (BSA: Fisher
Scientific) and sucrose 5% (MP Biomedicals, LLC). Plates were rinsed three times with
PBS, then GDNF standard (R&D Systems) or samples (conditioned culture medium or
harvested cells) were added to each well, and plates were incubated for two hours at room
temperature. The wells were washed with PBS and 100ng/ml anti-GDNF secondary
antibody conjugated to biotin (R& D Systems) was added and incubated for two hours at
room temperature. Following incubation the wells were washed three times with PBS and
beta-galactosidase conjugated to streptavidin (Molecular Probes) was added and the plates
were incubated for 20 minutes at room temperature. The wells were washed three times
and 1mg/ml chlorophenol red- -D galactopyranoside (CPRG: Roche Diagnostics GmbH)
was added and incubated at room temperature. Plate readings were taken every two hours
until the standard curve was obtained. Absorbance was measured at 575nm using an
absorbance plate reader (Gen5, BioTek). For each assay, a standard curve was calculated
from known GDNF concentrations.
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2.5.6. Immunocytochemistry
For detection of myosin, GDNF, and NGF, both cell types were allowed to grow
on coverslips up to 5-day-old for cardiac cells and 6-day-old or 7-day-old for myotubes.
Cells were washed with PBS and fixed with 2.4% (cardiac cells) or 4% (myotubes)
paraformaldehyde for 15 min at room temperature. Cells were washed three times for 5
minutes in PBS. Plates were blocked for one hour at room temperature. Following
blocking, cells were incubated in primary antibodies against GDNF, NGF, or myosin (for
cardiac cells, sarcomeric myosin heavy chain antibody FM-20 from Developmental
Studies Hybridoma Bank was used) at 4°C overnight. Cells were washed again with PBS.
Next, donkey anti-mouse or donkey ant-rabbit conjugated with Alexa Fluor 488, Alexa
Fluor 568 or Fluor 647, were added for two hours at room temperature. Concentrations of
each antibody or chemical were used according to manufacturer protocols based on the
particular experiment.
Procedures described by Yang and Nelson (2004) were used to examine GDNF
receptors (GFR-1) and acetylcholine receptors (AChRs) on myotubes. Primary GDNF
receptors polyclonal mouse anti-GFRα-1 (Santa Cruz Biotechnologies) and alpha
bungarotoxin (-btx) conjugated Alexa Fluor 488 (Molecular Probes) were used for
GFR-1 and AChRs, respectively. Concentrations of each antibody or chemical were used
according to manufacturer protocols. The cells were maintained in medium containing
antibodies or antagonists at 37°C in a standard incubator for 1hour. Cells were washed with
PBS and fixed with 2.4% (cardiac cells) 4% (myotubes) paraformaldehyde for 15 min at
room temperature. PBS containing 1% bovine serum albumin and 0.1% triton X-100 were
added to permeablize the cells for and block non-specific sites. Cells were washed in PBS,
and bound with secondary antibodies conjugated to AlexaFluor 488®, AlexaFluor 568®,
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or AlexaFluor 647®, for 2 hours at room temperature. Negative controls consisted of
cultures without primary antibodies added. Cells were washed with PBS and the coverslip
with cells were mounted on a glass slide with 50% glycerol/50%PBS and sealed. Images
were viewed using a Zeiss laser scanning confocal microscope (Zeiss LSM 510).

2.5.7. Western blot
The amount of GDNF in culture medium and in cells was determined by western
blot as previous described (Vianney and Spitsbergen, 2011). To examine GDNF protein,
culture medium samples or cell samples were loaded with Laemmli 2× loading buffer to
make a final volume of 20μl. Controls consisted of a protein ladder (New England
BioLabs), GDNF protein (positive control) and NGF protein (negative control). For
detection of other proteins, positive control was always the protein of interest, and the
negative control was other protein. All samples were boiled for 5 min and loaded into a
15% polyacrylamide gel. The gel was submerged and was run in separating buffer at two
different voltages (100V followed by 150V). The transfer of protein from the gel to the
polyvinylidene difluoride (PVDF; Invitrogen) membrane was performed at 12 V for 1 h.
The PVDF membrane was blocked with I-Block (Tropix) for 1 h at 4 °C on a shaking
platform. The membrane is then incubated with a primary antibody against GDNF (Santa
Cruz Biotechnologies) in I-Blocking buffer overnight at 4 °C on a rotating platform. The
membrane was washed 3 times, for 5, 10, and 20 min while shaking. The membrane was
then incubated with a HRP-conjugated secondary antibody (ECL; GE Healthcare) in IBlocking buffer for 1 h at room temperature, while shaking. GDNF protein was detected
with chemiluminescence and is visualized on BioMax XAR film (Kodak) with exposure
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times from 30seconds to 15 min, or protein detection was performed using Gel Logic 2200
Pro (Carestream, Molecular imaging).

2.5.8. Statistical analysis
Statistical analysis was performed using a student’s t-test and analysis of variances
(ANOVA). P values ≤ 0.05 were considered statistically significant. All data values are
reported as the mean ± standard error of the mean (SEM).
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CHAPTER 3

EFFECT OF ACETYLCHOLINE AND ELECTRICAL STIMULATION ON
GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR
PRODUCTION IN SKELETAL MUSCLE CELLS

3.1. INTRODUCTION
Glia cell line-derived neurotrophic factor (GDNF) was first purified by Lin et al.
(1993) as a survival factor for dopaminergic neurons. GDNF is widely distributed in
neuronal and non-neuronal tissues (Springer et al., 1995). GDNF exerts its survival effects
on other subpopulations of neurons in the central and peripheral nervous systems
(Henderson et al., 1994; Moore et al 1996; Trupp et al., 1995). Specifically, GDNF is
characterized as a survival factor for spinal motor neurons (Henderson et al., 1994). The
trophic factor is synthesize and release by skeletal muscle, and acts as a muscle-derived
neurotrophic factor for spinal motor neurons (Suzuki et al., 1998a). During development,
GDNF rescues motor neurons from programmed cell death (Oppenheim et al., 1995), acts
as a chemoatractant, and assists with motor axonal guidance to motor neuron target tissues
(Dudanova et al., 2010; Kramer et al., 2006). GDNF facilitates synaptic transmission
(Wang et al., 2001), maintains synaptic activity (Zwick et al., 2001), plays a role in
enhancing nerve recovery after injury (Cote et al., 2011; Dupont-Versteegden et al., 2004;
Hashimoto et al., 2005; Houenou et al., 1996; Naveilhan et al., 1997; Oppenheim et al.,
1995; Zhang et al., 2009) and muscle overexpressing GDNF displays hyperinnervation of
endplates (Nguyen et al., 1998). These findings support the hypothesis that motor neurons
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depend on GDNF as a target-derived neurotrophic factor and GDNF secreted by skeletal
muscle may be important for motor neurons survival (Angka et al., 2008; Bohn, 2004).
Although much is known about the effects of GDNF on motor neurons, little is
known about factors regulating GDNF synthesis and release by skeletal muscle.
Denervation of sketal muscle causes an increase in GDNF expression (Suzuki et al., 1998b;
Lie and Weis, 1998), while muscle cells co-cultured with neural cells in vitro secrete less
GDNF (Vianney and Spitsbergen, 2011). These findings suggest that the innervation status
of skeletal muscles plays a role in regulating the amount of GDNF produced by muscle.
In the present study the effect of the cholinergic agonists, acetylcholine (ACh) and
carbachol (CCh), on GDNF production by skeletal muscle were examined. The question
of whether electrical stimulation has a similar effect to that of the cholinergic agonists was
also investigated. The results suggest that treatment with ACh and/or short-term electrical
stimulation reduces GDNF secretion, while treatment with CCh or long-term electrical
stimulation enhances GDNF production by skeletal muscle.

3.2. EXPERIMENTAL PROCEDURE
3.2.1. Cell culture procedure
Unless otherwise stated, all chemicals were purchased from Sigma (Sigma-Aldrich,
St. Louis, MO, USA). The C2C12 mouse skeletal muscle cell line was purchased from
American Type culture collection (ATTC: Manassas, VA, USA). The C2C12 cell line was
extracted from 2-month old mouse thigh muscle and these cells have been used by
researchers because of their in vivo skeletal muscle phenotype, including expression of
contractile proteins (Ling et al., 2005; Yafel and Saxel, 1997). Culturing procedures were
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performed according to the ATCC protocols and as described by Vianney and Spitsbergen
(2011). Briefly, C2C12 myoblasts were initially seeded on 100-mm plates and maintained
in Dulbecco’s Modified Eagle’s medium (DMEM: ATCC) supplemented with 10% fetal
bovine serum and 1% antibiotic-antimycotic (Life Technologyies, Carlsbad, CA, USA).
Cells were incubated at 37°C in water-saturated atmosphere of 95% air and 5% CO2. For
experiments, myoblasts cells were seeded in 6-well plates (USA Scientific, Inco. Ocala,
FL, USA). Differentiation of myoblasts to myotubes was induced by replacing the growth
medium with DMEM supplemented with 10% horse serum and 1% antibioticantimyocotic. The medium was renewed every one to two days. All experiments were run
on myotubes that had been maintained in culture for 6 to 8 days.
3.2.2. Sample collection and cell harvesting
To determine GDNF protein concentration in culture medium, a 1 ml sample of
medium was collected from each culture dish at 2, 4, and 24 h following treatment and kept
at -20°C. To harvest cells, culture medium was removed, cells were washed with
calcium/magnesium-free buffer and 1 ml of sample buffer (a mixture of phosphate buffered
saline, 0.005% Tween-20, 0.5% bovine serum albumin, 0.1 mM benzethonium chloride, 2
mM benzemidine, 0.4 M NaCl, 2 mM EDTA and 164µl/100 ml aprotinin) was added to
each culture dish. The cells were scraped from the dish using a cell lifter. To examine
intracellular GDNF, cells were spun in a cold centrifuge at 13.5g and supernatant was
removed and stored at -20°C. GDNF protein concent in each experiment was measured by
an enzyme-linked immunosorbent assay (ELISA) as described below.
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3.2.3. GDNF protein detection by ELISA
Determination of GDNF protein content in culture medium and cell supernatant
was measured by ELISA. Briefly, GDNF primary antibody (1 mg/ml:R&D Systems,
Minneapolis, MN,USA) was added to 96-well ELISA plates and then incubated overnight
at room temperature. Plates were blocked with phosphate buffer saline (PBS)
containing1% bovine serum albumin (BSA: Thermo Fisher Scientific, Waltham, MA,
USA) and sucrose (5%). Plates were rinsed three times with wash buffer (a mixture of PBS
and 0.05% Tween-20), then GDNF standard (R&D Systems) or samples (conditioned
culture medium or harvested cells) were added to each well, and plates were in cubated for
two hours at room temperature. Plates were washed and 100ng/ml anti-GDNF secondary
antibody conjugated to biotin (R&D Systems) was added and incubated for two hours at
room temperature. Following incubation plates were washed and betagalactosidase
conjugated to streptavidin (Life Technologies) was added and incubated for 20 min at room
temperature. Plates were washed and 1mg/ml chlorophenolred-β-D galactopyranoside
(CPRG: Roche Diagnostics GmbH, Indianapolis, IN, USA) was added and incubated at
room temperature. Plate readings were taken every two hours until the standard curve was
developed. For each assay a standard curve was calculated from known GDNF
concentrations.
3.2.4. Detection of acetylcholine receptors using alpha-bungarotoxin
Procedures were as previously described in Vianney and Spitsbergen (2011), with
minor modification. Briefly, cells were grown on cover slips pre-treated with 0.1% gelatin
(Thelen et al., 1997). Cells were maintained at 37°C in a standard incubator and allowed
to differentiate into myotubes. To examine whether myotubes express AChRs, live cells
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were treated with alpha bungarotoxin (-BTX) using a procedure adopted from Yang and
Nelson (2004). Briefly, myotubes were treated with fresh medium containing 200 nM BTX conjugated to Alexa-FluorR 488 (Life Technologies) and maintained at 37°C in a
standard incubator for 1 h. Cells were washed and fixed with 4% paraformaldehyde for 30
min, were washed with PBS and the coverslip with cells was mounted on a glass slide with
50% glycerol/50%PBS. Images were captured using a Zeiss laser scanning confocal
microscope.
3.2.5. Treatment with acetylcholine or carbachol
Cells were grown as previously described. On the day of the experiment, fresh
medium containing acetylcholine or carbachol (ACh or CCh, respectively; 0.1 µM, 1 µM,
and 100 µM) was added to myotubes. Samples of conditioned culture medium and
harvested cells were taken after 2, 4, and 24 h. Control plates were processed in the same
manner except that no ACh or CCh was added. In a separate experiment, CCh was added
to myotubes for 5 min then removed and fresh culture medium was added. Samples of
conditioned culture medium and harvested cells were collected after 30 min. Both cells and
culture medium samples were stored at -20°C. GDNF protein content was measured by
ELISA.
3.2.6. Block of acetylcholine receptors with alpha-bungarotoxin
C2C12 myoblasts were grown on 12-well plates and allowed to differentiate into
myotubes. Myotubes were treated with fresh medium containing 200 nM unlabeled -BTX
(Biotium, Hayward, CA, USA) for 25 min. Following incubation with -BTX the cells
were washed twice with fresh culture medium and fresh medium containing 100 nM ACh
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or 100 nM CCh was added. Controls consisted of plates without treatments and plates that
were treated with 100 nM ACh or 100 nM CCh without -BTX. Samples were collected
at intervals of 2, 4, and 24 h. GDNF protein content was measured by ELISA.
3.2.7. Electrical stimulation of skeletal muscle cells
The approach of Marotta et al.,(2004) inspired the electrical stimulation apparatus
used in this work, including its use of switched semicircular electrodes as part of a culture
dish lid, a series coupling capacitor (0.47 µF rather than the 220 µF) and current sampling
resistors (approximately100 Ω). Following Donnelly et al. (2010) stainless steel electrodes
were used instead of platinum electrodes used by Marotta et al., (2004) and Thelen et al.
(1997). A Grass Technologies S88 stimulator provided voltage pulses to a custom interface
box. Electrodes were secured to the culture dish lid with bolts, which also provided
convenient wire connection points using wires with spade lugs. Within the interface box a
unity gain voltage buffer provided current to up to six pair of electrodes connected to six
switches, which enabled each pair of electrodes to be individually selected. Stimulator
pulse characteristics were experimentally selected to cause noticeable contraction of the
muscle cells. Cells were stimulated at 1Hz or 5Hz for 30 min, 90min, 12h, 24h, and
48h.Typical pulse amplitudes were in the range of 20–25 V, with approximate 30ms widths
at the voltage buffer output. Using this apparatus three wells were stimulated
simultaneously and three wells served as controls. All cultures were maintained at 37 °C
in water saturated incubator of 95% air and 5% CO2 during stimulation periods. GDNF
protein content was determined by ELISA.
In order to mimic the motor nerve firing, a separate set of experiments were
performed according to Eftmie et al. (1991). In these experiments, cells were stimulated at
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100Hz trains of pulses; 1s-duration applied once every 100s. The pulses strength were 1015mA and duration of 0.5 ms. Cells were stimulated for 30 min while being maintained in
the incubator as described above. Samples were taken between 0h and 48h. GDNF protein
content was determined by ELISA.
3.2.8. Block of voltage-gated sodium channels
In order to test whether voltage-gated sodium channels were important for the effect
of electrical stimulation on GDNF production, channels were blocked using tetrodotoxin
(TTX). For each experiment, fresh medium containing 100µM tetrodotoxin (TTX) was
added to myotubes and cultures were maintained for 30 min before electrical stimulation.
Cells were electrically stimulated and samples of conditioned culture medium and
harvested cells were collected at 0, 2, and 24 h following electrical stimulation.
3.2.9. Statistical analysis
Statistical analysis was performed using analysis of variance (ANOVA) followed
by Tukey’s test, or Student’s t-test. P values  0.05 were considered statistically significant.
All data values ae reported as the mean  standard error of the mean (SEM).

3.3. RESULTS
3.3.1. Effect of acetylcholine on GDNF production by skeletal muscle cells
In previous studies we showed that cholinergic neurons play a role in regulating
GDNF synthesis and release by skeletal muscle (Vianney and Spitsbergen, 2011). Here,
we sought to determine whether cholinergic neurons exert their effect via neurotransmitter
release. First, cell staining was performed to ensure that the myotubes express ACh
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receptors (AChRs). Fig. 3.1A shows that C2C12 skeletal muscle cells stain positively using
-BTX conjugated to AlexaFluor 488, suggesting that the skeletal muscle cells express
AChRs. Exposure of myotubes to ACh inhibited GDNF protein secretion. GDNF levels
secreted at 2 h were reduced to 70% of control but no effect of treatment with ACh was
observed following 24 h of treatment (Fig. 3.1B). Also, treatment with ACh had no effect
on intracellular levels of GDNF protein at 2 h (Fig. 3.1C) and 24h (data not shown).
The next experiments were designed to determine whether or not ACh induced its
inhibitory effects via AChRs. In this set of experiments, treatment with ACh reduced the
secretion of GDNF in culture medium to around 60% of control and pretreatment with BTX blocked the inhibitory effects of ACh on GDNF secretion (Fig. 3.1D). Treatment with
ACh and -BTX had no effect on GDNF production at 24 h (data not shown).
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Figure. 3.1 Effect of ACh on GDNF production by skeletal muscle cells. A.
Acetylcholine receptors on skeletal muscle cells (myotubes). Myoblast cells were grown
and allowed to differentiate into myotubes. Culture medium containing α-BTX (200nM)
conjugated to Alexa Fluor 488 (green) was added to myotubes and incubated for 1h in a
standard incubator. Following 1h of treatment cells were fixed with 4% paraformaldehyde
and viewed on a confocal microscope. White arrows show AChRs on myotubes in culture.
Effect of ACh on GDNF production by skeletal muscle cells. Myoblast cells were grown
and allowed to differentiate into myotubes. B–C, 7-day-old myotubes were treated with
culture medium containing ACh at concentrations of 0.1 µM, 1 µM, and 100 µM.
Conditioned culture medium and cells were collected at 2 h and 24 h. B. ACh inhibits
GDNF secretion following 2 h but not 24 h of exposure. C. ACh had no effect on
intracellular GDNF content. D. Blocking AChRs with α-BTX prevented the effects of ACh
on GDNF secretion at 2 h. An asterisk (*) indicates a significant decrease from control,
dollar sign ($) indicates a significant difference in GDNF levels between samples collected
at 2 h and that collected after 24 h, pound sign (#) indicates a significant difference in
GDNF levels between cells treated with or without α-BTX. Values are presented as means
 S.E.M, P  0.05, N=6.

3.3.2. Effect of carbachol on GDNF production by skeletal muscle cells
Since ACh is quickly degraded by acetylcholinesterase (AChE), we sought to test
whether CCh, a chemical that mimics ACh effects but is not broken down by AChE, would
exert similar effects to those of ACh. Interestingly, ACh and CCh had different effects on
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GDNF secretion by muscle cells following 2 h and 24 h of exposure. While ACh inhibited
GDNF secretion following 2h exposure and had no effect after 24 h, CCh increased GDNF
secretion at both time points (Fig. 3.2A). However, when CCh was added to the cells for
only 5 min and then removed, a significant decrease in GDNF secretion was observed 30
min following treatment (Fig.3.2A). Similar to what was observed for ACh, CCh had no
effect on intracellular GDNF protein content (data not shown). Pretreatment with α-BTX
abolished the action of CCh on GDNF secretion (Fig.3.2B).
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Figure. 3.2. Effect of carbachol on GDNF production by skeletal muscle cells. Sevenday-old myotubes were treated with culture medium containing CCh at concentrations of
0.1 µM, 1 µM, and100 µM. Cells were either treated with CCh for only 5 min, followed
by removal of treated medium and replacement with fresh culture medium, or the exposure
to CCh was prolonged up to 24 h. Conditioned culture medium and cells were collected at
30 min for a short-term exposure, and 2 h and 24 h for a long-term exposure. A. GDNF
secretion decreases in the sample collected 30 min following a 5 min exposure to CCh, but
increases 2 h and 24 h following exposure to CCh. B. Blocking AChRs with α-BTX
prevented the action of CCh. An asterisk (*) indicates a significant increase from control.
A dollar sign ($) indicates a significant decrease from control. Values a represented as
mean  S.E.M and P  0.05, N=4.
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3.3.3. Effect of electrical stimulation on GDNF production by skeletal muscle cells
Direct electrical stimulation can be used to elicit muscle contraction, bypassing the
effect of ACh. Electrical stimulation has also been shown to alter protein expression in
skeletal muscle (Bayol et al., 2005; Donnelly et al., 2010; Thelen et al., 1997). In this study,
cells were exposed to 24 V pulses of 30 ms duration, applied at frequencies of 1 or 5Hz.
With electrical stimulation, myotubes contracted synchronously at a rate similar to the
stimulation frequency. Cells viewed after the stimulation period were found to be intact
following all stimulation protocols. For these studies, 30 and 90 min were regarded as
short-term stimulation and 12-48 h of stimulation were regarded as long-term stimulation.
Fig. 3.3 summarizes the changes in GDNF production by skeletal muscle cells following
short-term and long-term electrical stimulation. Thirty minutes of electrical stimulation at
either 1 or 5Hz caused a significant inhibition in GDNF secretion by muscle cells, with no
difference in effect being observed between stimulation frequencies (Fig. 3.3A). Unlike
the effects observed following treatments with ACh or CCh, electrical stimulation also
altered intracellular GDNF protein content. Although stimulation at 1Hz and 5Hz
significantly decreased GDNF protein levels in cells, the effect following stimulation at
1Hz was more marked than that observed following stimulation at 5Hz (Fig. 3.3B). As the
duration of stimulation increased, the inhibitory effect on GDNF production was
diminished and changed to a stimulatory effect following 48 h of stimulation (Fig. 3.3A
and 3.3B). GDNF was also inhibited when cells were stimulated with 100Hz trains of
pulses for 30min (Fig. 3C).
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Figure. 3.3. Effects of electrical stimulation on GDNF production. Short-term electrical
stimulation decreases GDNF secretion (Panel A) and GDNF content in muscle cells (Panel
B). The inhibitory effect of electrical stimulation is reduced as the duration of stimulation
is increased. Electrical stimulation for 24 and 48h shifts the inhibitory effect of electrical
stimulation to a stimulatory effect leading to an increase in GDNF production. Stimulation
of the cells with 100Hz trains of pulses also had an inhibitory effect on GDNF secretion
(Panel C). An asterisk (*) indicates a significant decrease from control. A dollar sign ($)
indicates a significant increase from control. A pound sign (#) indicates a significant
difference on GDNF levels between 1Hz and 5Hz groups. Values are presented as mean 
S.E.M.
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3.3.4. Role of voltage-gated sodium channels
In order to test whether the effects that were seen with electrical stimulation on
GDNF production involved ion channels, we examined voltage-gated sodium channels
with electrical stimulation on GDNF production. Voltage-gated sodium channels were
blocked using tetrodotoxin (TTX). Thirty minutes of stimulation in the presence of TTX
was chosen because we sought to examine whether TTX could reverse the inhibitory effect
of electrical stimulation on GDNF production. Although GDNF production was still
inhibited following electrical stimulation, the results showed that the inhibitory effect was
significantly reduced following TTX treatment, both for GDNF secretion (Fig. 3.4A) and
GDNF content within myotubes (Fig. 3.4B).
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Figure. 3.4. Effect of blocking voltage-gated sodium channels in C2C12 myoubes.
Cells were electrically stimulated in the presence or absence of tetrodotoxin (TTX) for
30min. The inhibitory effect on GDNF production caused by electrical stimulation was
reduced in cells exposed to TTX. A. GDNF secreted into culture medium and B.
Intracellular GDNF. An asterisk (*) indicates a significant decrease from control and a
dollar sign ($) indicates a significant difference on GDNF levels between TTX-treated and
non-treated groups. Values are presented as mean  S.E.M. (P  0.05). N= 4
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3.4. DISCUSSION

The goal of the current study was to determine whether motor neurons may regulate
their own supply of neurotrophic factors produced by skeletal muscle via effects of the
neurotransmitter ACh and whether the regulatory effects of ACh are dependent on
electrical activity in the muscle tissues. The major findings suggest that: 1) Both ACh and
short-term electrical stimulation inhibited GDNF production by skeletal muscle. 2)
Carbachol, a chemical that mimics ACh action, inhibited GDNF production at early times
following exposure, while increasing GDNF production at later times following exposure.
3) The results suggest that both ACh and CCh act via AChRs, as blocking the receptors
prevented the action of both chemicals. 4) Blocking voltage-gated sodium channels with
TTX reduced the effect of electrical stimulation on GDNF production. 5) Finally, the
magnitude and direction (inhibition vs. excitation) of the effect of electrical stimulation
was dependent on the duration of stimulation, where short-term stimulation inhibited
GDNF production and prolonged stimulation enhanced GDNF production.
The inhibition of GDNF production caused by short-term depolarization may
explain results of previous studies which show that GDNF production is inhibited when
skeletal muscle is co-cultured with cholinergic neurons (Vianney and Spitsbergen, 2011).
The inhibitory effect of ACh or short-term electrical stimulation may also help explain why
GDNF mRNA levels increase in skeletal muscle following denervation (Lie and
Weis,1998), and why ACh inhibits extra cholinergic nerve branching during development
(An et al.2010). Taken together it can be suggested that signaling pathways activated

102

following skeletal muscle innervation, treatment with exogenous ACh, or short-term direct
electrical stimulation, inhibit GDNF production by skeletal muscle.
The inhibitory effect of short-term electrical stimulation appears to involve
activation of voltage-gated sodium channels, as blocking these channels with TTX partially
reversed the inhibitory effect. It is interesting to note that TTX was less effective at
blocking the effects of electrical stimulation on intracellular GDNF, possibly suggesting
that intracellular GDNF content may be regulated differently than secreted GDNF.
Unlike effects observed following treatment with ACh, exposure to CCh increased
GDNF secretion by the muscle. C2C12 skeletal myotubes used in the current study express
AChE (Choi et al., 2003; Lee et al.,2004; Siow et al.,2002; Tung et al.,2004), thus, these
differences may be due in part to differences in the way these molecules are degraded
(Taylor and Brown,1999). Unlike ACh, CCh is not broken down by AChE (Jankovic et al.,
1998). Because CCh is resistant to AChE, long-term exposure to CCh increases muscle
contraction (Protas et al., 1998) and increases the time-course of other cellular responses
(Jankovic et al.,1998, Longmore et al.,1986). Therefore, we suggest that the opposite
response of ACh compared to CCh, on GDNF expression by myotubes, may be due to the
differences in metabolism of the two drugs, as a very short-term exposure to CCh exerts
similar effects to that of ACh. If CCh continuously activates the muscle this may signal the
muscle to increase GDNF secretion.
A similar phenomenon was observed with short-term vs. long-term electrical
stimulation, where the inhibitory effect of electrical stimulation was diminished following
increased duration of stimulation, converting to a stimulatory effect following 24–48 h of
stimulation. These observations suggest that following prolonged treatment the effect of
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electrical activity on GDNF production changes from inhibition to stimulation. A
stimulatory effect following prolonged treatment, either with exposure to CCh or long-term
electrical stimulation, may help explain the increase in GDNF content found in skeletal
muscle following exercise training (Wehrwein et al.,2002, McCullough et al., 2011).
The results show that treatment with ACh, brief exposure to CCh, or short-term
electrical stimulation all inhibit GDNF secretion by muscle cells, while longer term
exposure to CCh or increased duration of electrical stimulation increases GDNF secretion
by muscle cells. The similarities in the pattern of response, early inhibition followed by
late stimulation, may suggest that both treatment modalities are altering GDNF secretion
via similar mechanisms. However, the observation that CCh can enhance GDNF secretion
following as little as 2h of exposure, while electrical stimulation does not increase GDNF
secretion until 48h of stimulation, may suggest that different signaling mechanisms are
involved. The observation that electrical stimulation alters both intracellular GDNF content
and secretion, while treatment with cholinergic agonists only affects GDNF secretion, also
supports the notion that different signaling mechanisms may be involved. Additional
studies are needed to elucidate the signaling pathways by which electrical and chemical
treatments alter GDNF secretion by skeletal muscle.
Previous work has demonstrated that fast and slow type skeletal muscles display
different changes in GDNF protein content in response to low intensity exercise and to low
frequency field stimulation (McCullough et al., 2011). Walk training or low frequency field
stimulation (0.1Hz) of skeletal muscle decreases GDNF protein content in extensor
digitorum longus, a muscle comprised primarily of fast-type muscle fibers, while these
stimuli increase GDNF protein in soleus muscle, a muscle comprised primarily of slow-
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type muscle fibers (McCullough et al.,2011). A switch from fast to slow muscle fiber-type
has been observed following electrical stimulation of C2C12 myotubes (Nedachi et al.,
2008); and these changes alter physiological demands of the cells in vivo and in vitro
(Williams and Neufer, 2011; Zebedin et al., 2004). Thus changes in muscle fiber-type could
also help to explain the change in response following long-term stimulation.
These findings, and results of studies by Xie et al. (1997), show that different
families of neurotrophic factors may be regulated differently by muscle depolarization. Xie
et al. showed that neurotrophin 3 expression in skeletal muscle increased with electrical
stimulation or treatment with ACh (Xie et al., 1997), while our result show that GDNF
production is inhibited by ACh or short-term electrical stimulation. Our observations that
a sizeable pool of intracellular GDNF is maintained in skeletal muscle and that intracellular
GDNF content is regulated differently than secreted GDNF may suggest that muscle retains
an intracellular store of GDNF that may be released under certain circumstances. This has
been shown to be the case with the neurotrophins (Poo, 2001), where these neurotrophic
factors appear to be synthesized, stored and released upon demand.
In summary, these results suggest that GDNF production in skeletal muscle cells is
regulated in an activity-dependent manner and can be modulated by chemical or electrical
stimulation. Furthermore, the results demonstrate that the regulatory effect may change
from an inhibitory effect on GDNF production at low levels of stimulation to an excitatory
effect with long-term stimulation, suggesting that levels of GDNF protein being produced
and/or secreted depend on physiological demands on the skeletal muscle cells.
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CHAPTER 4
DIFFERENTIAL REGULATION OF GDNF AND NGF IN ATRIAL
CARDIOMYOCYTES BY NEUROTRANSMITTER AND
ELECTRICAL STIMULATION

4.1. INTRODUCTION
Neurotrophic factors have been shown to play a key role in neuronal growth,
survival, and maintenance. In the peripheral nervous system, one major source of
neurotrophic factors are the target tissues found in the periphery (Trupp et al., 1995). It has
been shown that motor neurons in the periphery depend in part on the neurotrophic factors
supplied by their targets (Bohn, 2004; Zwick et al., 2001). The heart is a target tissue
supplied by both sympathetic and parasympathetic branches of the autonomic nervous
system, and it is the most innervated target tissue in the periphery (Mitchell, 1952). The
heart was also shown to express neurotrophic factors including nerve growth factor (NGF:
Crowley et al., 1994; Furukuwa et al., 1984; Govoni et al., 2011; Levi-Montalcini, 1953 &
1987; Rana et al., 2011).
The expression of NGF in the heart and its support of the autonomic nervous system
have been extensively examined. NGF was found to be critical for survival, nerve
patterning, and development of the sympathetic neurons innervating the heart (LeviMontalcini, 1987; Vo and Tomlinson, 1999). However, regulation of NGF expression in
relation to heart function is not fully understood (Reviewed by Govoni et al., 2011; Ieda
and Fukuda, 2009). Recent studies have also reported the expression of other neurotrophic
factors including GDNF family ligands in the mammalian heart (Hiltunen et al., 2000;
Martinelli et al., 2002; Rana et al., 2011). Results from other investigators have started
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shedding light on the preferences of autonomic neurons for different neurotrophic factors.
While neurturin (NRTN) a second member of the GDNF family was reported to be
exclusively associated with cholinergic (parasympathetic) neurons in the heart (Hiltunen
et al., 2000; Mabe et al., 2006), GDNF was shown to affect both noradrenergic
(sympathetic) and cholinergic (parasympathetic) neurons (Martinelli et al., 2002; Rana et
al., 2011).
GDNF levels have been shown to be elevated in chemically sympathectomized rats,
possibly to support sympathetic nerve regeneration (Martinelli et al., 2002). GDNF was
also shown to have neurotrophic effect on parasympathetic neurons in culture (Buj-Bello
et al., 1995) and was found to be essential for parasympathetic nerve development in vivo
and in vitro (Enomoto et al., 2000; Hasan, 2013). These observations suggest that GDNF
may play a significant role in supporting these two antagonizing branches of autonomic
systems. Although two GDNF family ligands are expressed in the heart and have been
shown to exert neurotrophic activity (Hiltunen et al., 2000; Hoover et al., 2004; Martinelli
et al., 2002), factors that regulate their synthesis and release are yet to be understood. This
current study examines the regulation of expression of GDNF and NGF in cardiac muscle.
The question being asked is whether the regulation of GDNF and NGF production by
cardiac muscle is regulated in a similar manner.
In the current study, we utilized HL-1 cells, a murine atrial-derived cell line that
continuously contracts in culture: 1) to explore the expression of GDNF and NGF, 2) to
examine the roles of acetylcholine and norepinephrine on GDNF and NGF expression, and
3) to study the effect of electrical activity on levels of GDNF and NGF expression.
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Results suggest that GDNF and NGF may be regulated differently by
neurotransmitters released by sympathetic or parasympathetic neurons. The effect of direct
electrical stimulation on GDNF and NGF production depends on the frequency and
duration of stimulation. The results also suggest that HL-1 atrial cells can serve as useful
model that can be used to study the cellular regulation of neurotrophic factor expression in
the heart.

4.2. EXPERIMENTAL PROCEDURE
The experimental procedures used in this study have been explained in detail
in chapter two. However, the following are brief explanations, including modifications
for specific sets of studies under this section. All drugs were purchased from Sigma
unless otherwise noted.
4.2.1. Cell culture procedure
HL-1 cells were used in this study because they display in vitro phenotypic
characteristics of adult cardiomyocytes, including the ability to contract continuously in
culture (Claycomb et al., 1998). The cells were obtained as a gift from Dr. W. Claycomb
(Lousiana State University Medical Center, New Orleans, LA) and were grown according
to Dr. Claycomb’s Lab protocol (personal communication) with minor modifications.
Briefly, culture medium consists of Claycomb medium supplemented with 10% fetal
bovine serum, 1% antibiotic-antimycotic (Life Technologies, Grand Island, NY), 1%
norepinephrine and 1% L-glutamine. All culture plates were obtained from USA
Scientific, Inc. Ocala, FL, unless stated otherwise. Before seeding cells, plates were coated
with a mixture of 0.02% gelatin (Fisher Scientific, Fair Lawn, NJ) and 0.5% fibronectin.
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HL-1 cells were initially seeded on 100-mm plates for 4–5-days. This time in culture
allowed the cells to reach confluence and differentiate to become contractile. To remove
the cells from 100-mm plates, 3 ml of 0.05% trypsin/EDTA was added twice. The first
addition of trypsin/EDTA was followed by 2 minutes incubation in standard incubator,
followed by a 3 minute incubation after the second addition of trypsin/EDTA. Equal
amount of soybean trypsin inhibitor was added to stop the activity of trypsin. The plate
then was rinsed using 6 ml of wash medium (consists of Claycomb medium supplemented
with 5% FBS and 1% antibiotic-antimycotic). Cells were centrifuged at 500 x g for 5
minutes. Supernatant was removed by aspiration and the cell pellets were gently
suspended in 3 ml of supplemented Claycomb medium. The cells then were transferred to
6- or 12-well plates for experimental procedures. All treatment procedures were
performed on differentiated, contracting cells. All cultures were maintained at 37°C in a
water-saturated atmosphere of 95% air and 5% CO2. The medium was renewed daily.
4.2.2. Sample collection and cell harvesting
All treatments were performed on differentiated, contracting cells. To determine
GDNF or NGF protein concentration in culture medium, a 1ml sample of culture medium
was collected from each culture dish between 0, 1, 2, 4, and 24 hours following treatment
and kept at -20°C. To harvest cells, culture medium was removed, cells were washed with
Dulbecco’s phosphate buffered saline (DPBS). The cells were scraped from the dish using
a cell lifter (USA Scientific). To examine intracellular GDNF or NGF, cells were spun in
a cold centrifuge at 13.5 x g and supernatant was removed and stored at -20°C. GDNF or
NGF protein content were measured by an enzyme-linked immunosorbent assay (ELISA).
GDNF or NGF protein molecular sizes were determined by western blot analysis.
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4.2.3. GDNF protein detection by ELISA
The GDNF ELISA procedure was performed as previously described in Chapter 3
and in Vianney and Spitsbergen, (2011). To determine NGF concentration in cells, NGF
primary antibody (0.4µg/ml: R&D Systems, Minneapolis, MN, USA) and anti-NGF
secondary antibody conjugated to biotin (100ng/ml: R&D Systems, Minneapolis, MN,
USA) were used. Plate readings were taken every 30minutes until the standard curve was
developed. For each assay a standard curve was calculated from known NGF
concentration.
4.2.4. Protein localization by Immunocytochemistry
Procedures were adopted as previously described in Vianney and Spitsbergen,
(2011) with minor modification. Briefly, cells were grown on cover slips pre-coated with
gelatin/fibronectin. Cells were maintained at 37°C in a standard incubator and allowed to
differentiate. Differentiated cells were washed with Dulbecco’s phosphate buffer saline
(DPBS) and fixed with 2.5% paraformaldehyde for 30 minutes at room temperature. Cells
were then washed three times for 5 minutes each with DPBS. Cover slips were blocked
with PBS containing 4% bovine serum albumin and 0.2% triton X-100 for 10 minutes.
Cells were then incubated at 4° C overnight with a 1:100 dilution of goat anti-NGF
(Abcam, Cambridge, MA), rabbit anti-GDNF (Santa Cruz Biotechnology, CA), or
monoclonal antibody to sarcomeric myosin heavy chain (MF 20, Developmental Studies
Hybridoma Bank, Iowa). Cells bound with primary antibodies were washed in PBS,
followed by binding to secondary antibodies consisting of donkey anti-rabbit IgG
conjugated to AlexaFluor® 488 (1:100), or donkey anti-mouse IgG conjugated to
AlexFluor® 568 (1:100) and donkey anti-rabbit conjugated to AlexaFluor 647® (1:50)
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(Life Technologies). Negative controls consisted of cover slips containing cell to which no
primary antibodies were added. Slides were incubated for 2 hours at room temperature.
Coverslips with cells were washed and mounted on a glass slide with 50%s glycerol/50%
PBS and sealed. Images were captured using a Zeiss LSM 510 laser scanning confocal
microscope.
4.2.5. Detection of GDNF protein size by Western blotting analysis
The size of the GDNF protein was determined by Western blotting, as previous
described in Vianney and Spitsbergen (2011), but with some modifications. Culture
medium and cell samples were loaded with Laemmli 2X loading buffer to make a final
volume of 20μl. Controls consisted of a protein ladder (New England BioLabs, Ipswich,
MA, USA) and GDNF protein (positive control, R&D Systems). The samples were boiled
for 5 min and then loaded into a 15% polyacrylamide gel. The gel was run in separating
buffer at two different voltages, 100V and 150V, respectively. The transfer of protein from
the gel to the polyvinylidene difluoride (PVDF; Life Technologies) membrane was
performed at 15V for 2h. The PVDF membrane was blocked with I-Block (Applied
Biosystems, Foster City, CA, USA) for 1h at room temperature on a shaking platform. The
membrane was incubated with a primary antibody against GDNF or NGF (Santa Cruz
Biotechnologies) in I-Blocking buffer overnight at 4 °C on a shaking platform. The
membrane was washed 3 times, for 5, 10, and 20 min, while shaking. The membrane was
then incubated with an anti-rabbit HRP-conjugate secondary antibody (ECL; GE
Healthcare) in I-Blocking buffer for 2h at room temperature, while shaking. GDNF or NGF
protein bands were detected with Gel Logic 2200 Pro (Carestream, Molecular imaging)
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with exposure time of 3–15 minutes, or with chemiluminsescence visualized on BioMax
XAR film (Sigma) with exposure times of 1-3 minutes.
4.2.6. Treatment with neurotransmitters
Cells were grown on 12-well plates as previously described. On the day of each
experiment, fresh culture medium containing norepinephrine (NE: 0.1mM and 1mM) or
acetylcholine (ACh: 0.1µM, 1µM, 100µM) was added to differentiated HL-1 cells.
Samples of conditioned culture medium and harvested cells were taken after 30 min, 1h,
2h, 4h and 24h. Control plates were processed in the same manner except that no NE or
ACh was added. Both harvested cells and culture medium samples were stored at -20°C.
GDNF or NGF protein content was measured by ELISA.

4.2.7. Blockade of NE and ACh effects
HL-1 cells were grown on 12-well plates and allowed to differentiate and start
contracting. Cells were treated with fresh medium containing 100µM atropine or 100µM
propranolol for 25 min. Following incubation with antagonists, the cells were washed twice
with fresh culture medium and fresh medium pretreated with NE or ACh was added.
Controls consisted of plates without treatments and plates that were treated with NE or
ACh without antagonists. Samples were collected at intervals of 30min, 1h, 2h, 4h, and
24h. GDNF or NGF protein content was measured by ELISA.

4.2.8. Electrical stimulation
Electrical stimulation apparatus used in this work based on Marotta et al., (2004)
included the use of switched semicircular electrodes as part of a culture dish lid, a series
coupling capacitor (0.47µF) and current sampling resistors (approximately 100).
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Following Donnelly et al. (2010) stainless steel electrodes were used instead of platinum
electrodes used by Marotta et. al. (2004) and Thelen et al. (1997). A Grass Technologies
S88 stimulator provided voltage pulses to a custom interface box. Electrodes were secured
to the culture dish lid with bolts, which also provided convenient wire connection points
using wires with spade lugs. Within the interface box a unity gain voltage buffer provided
current to up to six pair of electrodes connected to six switches, which enabled each pair
of electrodes to be individually selected. Cells were stimulated at 1Hz or 5Hz for 30min,
90min, 12h, 24h, and 48h. Typical pulse amplitudes were in the range of 20-25V, with
approximate 30 ms widths at the voltage buffer output. Using this apparatus, three wells
were stimulated simultaneously and three wells served as controls. All cultures were
maintained at 37°C in water-saturated incubator of 95% air and 5% CO2 during stimulation
periods. GDNF or NGF protein content was determined by ELISA.

4.2.9. Statistical analysis
Statistical analysis was performed using a student’s t-test or analysis of variance
(ANOVA) followed by Tukey’s test. P value ≤ 0.05 were considered statistically
significant. All data values are reported as the mean  standard error of the mean (SEM).

4. 3. RESULTS
4. 3. 1. Characterization of GDNF and NGF
We first observed the growth of atrial cells and found that contraction starts on day
2 to 3, when cells start fusing to form a single layer. Figure 4. 1 panel (A) shows the seeded
HL-1 cells 24h after sub-culturing (1-day-old); no contraction is observed at this stage of
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growth. Figure 4.1 panel (B) shows 4-day-old cells, at this stage cells have fused to make
a single layer and contract continuously.
The results confirmed that HL-1 cells express GDNF and NGF and that expression
starts early after seeding; that is, both non-contractile and contractile cells were shown to
synthesize the neurotrophic factors. Figure 4.1 panel (C) and panel (D) show 1-day-old and
4-day-old HL-1 cells, respectively, immunolabeled for GDNF and NGF. Both GDNF and
NGF seem to colocalize with sarcomeric myosin but the proteins do not colocalize with
each other (Fig. 4.1C, panel II-IV & Fig. 4.1D, panels II-IV). In addition, GDNF in 1-dayold cell seem to be mostly localized in the nucleus compare to the 4-day-old cells. GDNF
and NGF produced by HL-1 cells were also released into culture medium. Western blotting
analysis was performed to determine the molecular size(s) of both GDNF and NGF that
are produced by HL-1 atrial cells. Results showed that the cell express GDNF and NGF of
the molecular sizes of about 45kDa and 27kDa, respectively, panel (E).
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Characterization of GDNF and NGF in HL-1 cells
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Figure 4.1. HL-1 cells express GDNF and NGF. Cells grown to full confluence started
III
I
to contract continuously in culture. Panel A, shows non-contractile (1-day-old) and panel
B, shows contractile (4-day-old) HL-1 cells as viewed at 20x magnification, bar = 30µm.
For immunocytochemical processing, cells were grown on cover slips pre-treated with
gelatin/fibronectin. Cells were fixed and bound with antibody against sarcomeric myosin
heavy chain, goat anti-NGF, and rabbit anti-GDNF, followed by incubation in secondary
antibodies conjugated to Alex Fluor® 568 (donkey anti-mouse IgG), AlexaFluor® 488
(donkey anti-goat), or Alex Fluor® 647 (donkey anti-rabbit IgG). Slides were viewed using
a laser scanning confocal microscope (Zeiss LSM 510). Panel C, shows non-contractile
(1-day-old) and panel D, contractile (4-day-old) cells. For both C and D: panels I,
sarcomeric myosin (red); II, NGF (green); III, GDNF (blue); IV, overlay. Panel E, GDNF
and NGF molecular sizes, as detected by Western blot analysis. GDNF band is ~ 45kDa,
and NGF band is ~27kDa.

GDNF and NGF protein released into culture medium was quantified by ELISA.
Neurotrophic factor levels retained in cells and that secreted into culture medium were
shown to differ. The cells retained higher concentrations of intracellular GDNF or NGF
than was released into culture medium (Fig. 4.2A panels I & II). It was also observed that
the levels of GDNF and NGF synthesized or secreted by the cells significantly differ. The
levels of GDNF secreted were about 200-300pg/ml compared to NGF which ranged from
20-30pg/ml (Fig. 4.2B). Similarly, intracellular GDNF was about 300-500pg/ml, compared
to NGF content of 30-40pg/ml (Fig. 4.2C).

126

Intracellular and secreted GDNF and NGF content in HL-1 cells
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Figure 4.2A. Levels of GDNF and NGF produced in HL-1 cells in culture. Cells were
grown in 12-well plates and allowed to differentiate into contractile cells. GDNF and NGF
protein content was determined by ELISA. HL-1 cells retain more intracellular GDNF and
NGF than they release into culture medium. Panel I, GDNF and panel II, NGF. Values
are presented as mean  S.E.M. P  0.05, N=8.
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GDNF and NGF secreted into culture medium
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Figure 4.2B-C. Levels of GDNF and NGF produced by HL-1 cells in culture. Cells
were allowed to differentiate into contractile cells as in A above. GDNF and NGF protein
content was determined by ELISA. HL-1 cells express higher levels of GDNF than NGF.
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B, GDNF and NGF secreted into culture medium and C, GDNF and NGF retained in cells.
Values are presented as mean  S.E.M. P  0.05, N = 8.

4.3.2. Effects of norepinephrine on GDNF and NGF production in HL-1 cells
To test whether sympathetic neurons are involved in regulating GDNF and NGF
production in HL-1 atrial cells, the cells were treated with different concentrations of
norepinephrine (NE), (0.1mM, or 1mM). The results showed that the neurotransmitters
appeared to have opposite effects on GDNF protein expression. GDNF protein content
significantly increased in culture medium in samples collected after 2 hours following NE
treatment (Fig. 4.3A & 4.3B). Also, it was noted that although both 0.1mM and 1mM
increased GDNF, the higher concentration (1mM) significantly increased levels of GDNF
about 8-fold (Fig. 4.3B). Contrasted with 2h samples, there was a significant decrease on
GDNF protein levels in culture medium samples collected 24 hours after NE treatments
(Fig.4.3C). For both time points, propranolol, a -adrenergic receptor antagonist, did not
reverse the action of NE on GDNF production (Fig. 4.3A-C). Similar results were observed
for intracellular GDNF (data not shown).
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Effects of NE on GDNF secretion by HL-1 cells at 2h
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Figure 4. 3. Effect of norepinephrine on GDNF production. Cells were grown on 12well plates and allowed to differentiate as in previous sections. Cells were treated with NE
alone or NE with propranolol. GDNF protein content was measured by ELISA. A & B, NE
increases GDNF secretion at 2h. C, NE decreases GDNF in 24h samples. Propranolol
failed to reverse the action of NE, A-C. An asterisk (*) indicates a significant increase from
control. A ($) sign indicates a significant decrease from control, P 0.05. Values are
presented as mean  S.E.M, N= 6.

Results also showed that NE had no effect on NGF protein synthesized and released
in culture medium 2h following NE treatment (Fig. 4.4A). However, high concentration of
NE (1mM) showed a significant increase in NGF protein in culture medium samples
collected 24h after treatment (Fig. 4.4B). The effect of NE treatment on intracellular NGF
was similar (data not shown).
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Effect of Norepinephrine on NGF production
in HL-1 cells
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Figure 4.4. Effect of norepinephrine on NGF production. Differentiated cells were
treated with NE alone or NE with propranolol (Pro). A. NE had no effect on NGF
production at 2h. B. Treatment with 1mM NE increased NGF secretion at 24h. A-B.
Propranolol had no effect on NGF production. NGF protein content was quantified by
ELISA, P ≤ 0.05. Values are presented as mean  S.E.M, N= 6.

4.3.3. Effect of acetylcholine on GDNF and NGF in HL-1 cells
Next, we asked whether cholinergic neurons may regulate GDNF or NGF in the
heart. In order to examine whether parasympathetic nerve fibers innervating the heart play
a role in regulating GDNF or NGF expression, cells were treated with ACh at 1 or 100µM.
Samples were collected between 30min to 4h as in previous studies (Chapter 3 and Vianney
et al., 2014), ACh showed no effect after 24h. Treatment with ACh had opposite effects on
GDNF and NGF expression in HL-1 cells. While application of 1µM ACh significantly
decreased GDNF protein secretion (Fig. 4.5A) and content in cells (Fig. 4.5B), the same
concentration of ACh increased levels of NGF protein in culture medium and cells (Fig.
4.5A and 4.5B).

133

Effects of acetylcholine on GDNF and NGF production by HL-1 cells
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Figure 4.5 A-B. Effect of ACh on GDNF and NGF production. Cells were grown as in
previous experiments.

A. 1µM ACh decreases GDNF and increases NGF content in

culture medium. B. Similar results were observed for intracellular GDNF and NGF. An
asterisk (*) indicates a significant increase and ($) sign indicates a significant decrease.
Values are presented as mean  S.E.M, N= 6.

Application of 100µM ACh decreased both NGF and GDNF secretion (Fig. 4.5C).
The effect of ACh on NGF release seemed to be time dependent as the reduction in
secretion increased with time, from no effect at 30min to about 90% reduction at 4h (Fig.
4.5C). The reduction in intracellular NGF was only significant at 4h (Fig. 4.5D). Cells
were also treated with atropine, a non-specific antagonist for mAChRs to block the effect
of ACh. Results showed that atropine failed to reverse the action of ACh on NGF (data not
shown) and GDNF production (Fig. 5E).
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Effects of acetylcholine on GDNF and NGF production by HL-1 cells
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Figure. 4.5C-E. Effect of ACh on GDNF and NGF production. Cells were grown and
allowed to differentiate as in previous experiments. C. ACh (100µM) decreases GDNF
and NGF secretion into culture medium. D. The same concentration of ACh decreases
intracellular NGF and GDNF. Atropine shows no effect on the production of GDNF (E)
and NGF (data not shown). A dollar ($) sign indicates a significant decrease from control,
P 0.05. Values are presented as mean  S.E.M. N = 6.

4.3.4. Effect of electrical stimulation
Short-term stimulation was defined as stimulation applied for 30 and 90 min
whereas 12 to 48 hours of electrical stimulation was regarded as a long-term electrical
stimulation. Cells remained healthy and intact during short- and long-term electrical
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stimulation. Stimulation at 1Hz for 30 or 90 min resulted in a rapid increase in secretion of
both GNDF (140% of control) and NGF (120% of control). The excitatory effect shifted to
an inhibitory effect when the cells were stimulated for 12 – 48 hours (Fig. 4.6A).
Intracellular GDNF and NGF were elevated when cells were stimulated for 30 minutes and
significantly declined when cells were stimulated for 12, 24, and 48 hours (Fig. 4.6B).

Effects of 1Hz electrical stimulation on GDNF and NGF production
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Figure. 4.6 A-B. Effect 1Hz electrical stimulation on GDNF and NGF production.
Cells were grown in 6-well plates and allowed to differentiate. Cells were stimulated at
1Hz for 30min, 90min, 12h, 24h, and 48h. Short-term stimulation exerts an excitatory
effect, while the long-term stimulation has an inhibitory effect on GDNF and NGF
expression in HL-1 cells. GDNF and NGF secreted in culture medium, A, and intracellular
GDNF and NGF, B. Protein content of GDNF or NGF was determined by ELISA. Asterisk
(*) indicates a significant increase and a dollar sign ($) indicates a significant decrease for
both GDNF and NGF. Values are presented as mean  S.E.M. P 0.05, N= 6.

The activity dependency of trophic factor production has been documented (Poo,
2001). To examine whether increased cardiomyocyte activity would alter GDNF and NGF
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protein synthesis and release, the frequency of stimulation was increased to 5Hz. Results
showed that a 5Hz frequency appeared to have different effects on GDNF and NGF during
short-term electrical stimulation. GDNF secretion in HL-1 cells was inhibited about 20%
at all time points, while a significant increase in NGF secretion was observed at 30min of
electrical stimulation followed by a gradual decline (Fig. 4.6C). Intracellular GDNF was
reduced about 20% in electrically stimulated cells (Fig. 4.6D). Also a brief rise to
intracellular NGF was observed at 90min of stimulation, followed by a decline when cells
were stimulated for 12 to 48hrs (Fig. 4.6D).

Effects of electrical stimulation on GDNF and NGF production in HL-1 cells at 5Hz
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Figure 4.6 C-D. Effect of 5Hz electrical stimulation on GDNF and NGF production.
Stimulation at 5Hz increased NGF secretion at 30min and decreased NGF and GDNF
secretion at 24 and 48h. An asterisk (*) indicates a significant increase and a dollar sign
($) indicates a significant decrease for GDNF or NGF. Values are presented as mean 
S.E.M. P 0.05, N=6.

4.4. DISCUSSION
In the current study we examined regulation of expression of the neurotrophic
factors GDNF and NGF in HL-1 atrial cells. The levels of GDNF and NGF protein contents
were measured following treatments with neurotransmitters or direct electrical stimulation.
Results from this study suggest that acetylcholine, norepinephrine, and electrical
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stimulation regulate GDNF and NGF production in HL-1 cells. The major observations
include that 1) acetylcholine and norepinephrine have differential effects on GDNF and
NGF production by HL-1 cells. 2) The direction of effect on GDNF or NGF production
levels changes with the duration of exposure to and/or concentration of a neurotransmitter.
3) Low frequency electrical stimulation has similar effect on both GDNF and NGF
production by the cells; whereas, high frequency electrical stimulation has opposite effects.
4) The excitatory or inhibitory effects on GDNF or NGF expression levels depends on
duration and/or frequency of stimulation.
HL-1 cells were developed to serve as an in vitro model of adult atrial myocytes
(Claycomb et al., 1998; White et al., 2004). The cells have been used in various studies
including those examining cardiomyocyte growth (Brady et al., 2007; Nibbelink et al.,
2007), cell signaling (Discoll et al., 2006), metabolism (Palanivel et al., 2006; Pineiro et
al., 2005), electrophysiology (Yang et al., 2005), and response to pharmacological
treatments (Chaudary et al., 2004). Here we report that HL-1 cells also express GDNF and
NGF, neurotrophic factors that are utilized by sympathetic and parasympathetic neurons
(Levi-Montalcini, 1987; Martinelli et al., 2002). Expression of GDNF and NGF proteins
in HL-1 cardiomyocytes are observed in all times in cultures. However, the dynamics of
GDNF and NGF protein production by HL-1 cells differ significantly. This suggests that
each neurotrophic factor is regulated independently and possibly depends on demand for
each neurotrophic factor.
We also examined whether neurotransmitters that are released by sympathetic and
parasympathetic neurons regulate GDNF and NGF expression in HL-1 cells. Our results
suggest that acetylcholine and norepinephrine have effects on production of GDNF and
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NGF indicating that the neurotransmitters have a role in regulating the synthesis and
secretion of the neurotrophic factors in cardiac muscle. Interestingly, GDNF and NGF are
regulated in opposite manner by these neurotransmitters. We also found that the direction
of the effects of each neurotransmitter depends on the duration of exposure and the
concentration of neurotransmitter; with higher concentrations of norepinephrine causing a
greater activation of GDNF secretion. Long-term exposure to norepinephrine results in
inhibition of GDNF secretion, while increasing NGF production. One of the interpretations
may be that changes in GDNF and NGF production with time may depend on changes in
neural demand.
Treatments with norepinephrine appear to upregulate NGF in astroglial and
fibroblast cells (Furukuwa et al., 1989). Other studies however, have showed that
administration of norepinephrine resulted in decreasing NGF in iris (Hellweg et al., 1988),
brown adipocytes (Nisoli et al., 1996), cardiomyocytes (Kaye et al., 2000), and heart
(Kimura et al., 2010; Qin et al., 2002). Similar to the observation in the current study, in
these studies, time and concentration of norepinephrine were shown to be important factors
in determining the direction of changes in NGF in tissues.
Decreased production of GDNF following treatment with acetylcholine is a similar
effect to what has been observed in skeletal muscle (McCullough, 2011; Vianney et al.,
2014). This effect of acetylcholine on GDNF production may help explain the inhibitory
effect of cholinergic neurons on GDNF production in skeletal muscle (Vianney and
Spitsbergen, 2011).
We also observed that when high concentration of carbachol, an acetylcholine
agonist, was applied to HL-1 cells, the rate of contraction of the cells decreased from two
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beats per second (120bpm) to ~0.3 beats per seconds (18bpm). Slowing of heart rate has
been shown to be mainly associated with activation of M2 muscarinic acetylcholine
receptors (mAChRs) (Stengel et al., 2000). In this study, treatment of HL-1 cells with
acetylcholine causes GDNF production to decrease. It may be suggested that GDNF
production in cardiac muscle is activity-dependent and the neurotrophic factor is regulated
by acetylcholine via M2 receptors. On the other hand, acetylcholine acts on upregulating
NGF production, which is predominantly associated with sympathetic fibers that raise heart
rate.
Adrenergic and muscarinic receptor blocking agents, propranolol and atropine used
in this study, show small effects. One of the reasons may be the concentrations used.
Another reason may be the specificity of the receptors as propranolol and atropine are nonspecific blocking agents. Future studies will consider dose responsive curves to determine
the minimum and maximum effect of these agents. Also, the studies will use specific
blocking agents for adrenergic receptors as well as muscarinic receptors.
One of the aims of electrical stimulation studies was to bypass the action of
neurotransmitters in the signaling cascades that may be regulating GDNF or NGF.
Expression of GDNF and NGF is also regulated by electrical activity (Rana et al., 2011;
Saygili et al., 2011). In this study, we found that the effect of electrical stimulation is not
uniform, rather, the direction of the effects changes with frequency and duration of
exposure. The rise and fall of neurotrophic factor production observed with electrical
stimulation, can be correlated with a biphasic effect observed in heart. The physiological
response to ACh was believed to be caused by action of both excitatory and inhibitory
pathways utilizing M1, M2, or M3 receptors, respectively (Kitazawa et al., 2009; Tanaka et
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al., 2001). These receptors in turn, are coupled with different G-proteins that are involved
in stimulatory or inhibitory pathways (Wang et al., 2004). Because electrical stimulation
bypasses the mAChRs activation step, it will be of interest to examine whether the increase
and decrease of GDNF production that are caused by a short- and long-term electrical
stimulation, involve the G-proteins that are responsible for inhibitory or excitatory
pathways.
In summary, the information presented here confirms that HL-1 atrial cells
synthesize and secrete GDNF and NGF, and the production of these neurotrophic factors
is regulated by acetylcholine, norepinephrine, and electrical stimulation. The results also
show that the concentration of the neurotransmitters, frequency of electrical stimulation,
and duration of treatments are the key factors in regulating the levels of GDNF and NGF
production in HL-1 atrial cells. The results suggest that HL-1 cells can serve as useful
model for the study of cellular regulation of neurotrophic factors in the heart. Finally, the
results also suggest that GDNF and NGF production by cardiac muscle cells may be
differentially regulated by sympathetic and parasympathetic nervous system via
neurotransmitter release.
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CHAPTER 5
A COMPARISON OF EFFECT OF NEUROTRANSMITTER AND ELECTRICAL
STIMULATION ON GLIAL CELL LINE-DERIVED NEUROTROPHIC
FACTOR EXPRESSION IN VOLUNTARY AND
INVOLUNTARY MUSCLE

5. 1. INTRODUCTION

Glial cell line-derived neurotrophic factor (GDNF) is regarded as a potent survival
factor for sub-populations of neurons including somatic and autonomic motor neurons.
These neurons have been shown to depend, in part, on GDNF synthesized and secreted by
their target tissues (Henderson et al., 1994; Martinelli et al., 2002; Shneider et al., 2009).
It has been shown that a number of different tissues in the periphery express GDNF (Moore
et al., 1996; Sariola and Saarma, 2003). However, these target tissues differ in their
composition, function, and in the case of different muscle cell types, their contractile
characteristics. Whether the processes regulating GDNF production in these different
tissues is similar or different is poorly understood.
Neuronal-muscle co-culture studies suggest that neurons may regulate the levels of
GDNF synthesized and/or secreted by skeletal muscle (Vianney and Spitsbergen, 2011).
Also, acetylcholine, a major neurotransmitter released by cholinergic neurons, has been
shown to regulate GDNF production in skeletal muscle (Vianney et al., 2014). These two
observations lead to the hypothesis that GDNF in target tissues may be in part, regulated
by neurons via neurotransmitter release. Neuronal populations innervating muscle tissues
differ in the type of neurotransmitters they release and the effects those transmitters exert
on muscle contractile activity.
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Preferential utilization of different neurotrophic factors by different branches of the
nervous system has been suggested. In the somatic nervous system, cholinergic motor
neurons have been shown to depend on GDNF secreted by skeletal muscle (Angka et al.,
2008), while in the heart, GDNF supports both sympathetic and parasympathetic fibers
(Enamoto, et al., 2000; Martinelli et al., 2002). Nerve growth factor (NGF) has been shown
to be primarily associated with the sympathetic nerves (Heumann et al., 1984; Habecker et
al., 2008). Neurturin (NTRN), another member of GDNF family ligands, was shown to be
exclusively associated with cholinergic neurons in the autonomic nervous system (Hiltunen
et al., 2000; Hiltunen and Airaksinen, 2004; Hoover et al., 2004; Mabe and Hoover, 2009).
It is of interest to determine whether expression of these neurotrophic factors is regulated
in a similar fashion in different target tissues. A better understanding of processes
regulating GDNF expression in different target tissues may help to identify potential roles
for altered GDNF expression in the development of nervous system dysfunction with
disease and aging.
The current study examines GDNF expression in skeletal and cardiac muscle cells;
these cells were used as study models for voluntary and involuntary muscles. The study
examines and compares the effect of acetylcholine, a neurotransmitter released by both
cholinergic neurons in the somatic and autonomic systems. Also, the effect of direct
electrical stimulation (ES) on GDNF production in both muscle cell types is investigated.
The similarities and differences between the effects of acetylcholine with that of electrical
stimulation, on GDNF regulatory processes are discussed. The results suggest that
electrical stimulation and exposure to acetylcholine cause different effects on GDNF
expression in voluntary and involuntary muscles.
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5. 2. EXPERIMENTAL PROCEDURE
This study was aimed at comparing GDNF production in voluntary and involuntary
muscles at the cell level. To ensure controlled experimentation, experiments on voluntary
and involuntary muscle cells were performed side-by-side to reduce variability that could
occur if each cell type were examine alone. C2C12 skeletal muscle cells were selected as
a model for voluntary muscle and HL-1 cardiac muscle cells were selected as a model for
involuntary muscles.

5.2.1. HL-1 cell culturing
The HL-1 cells were obtained as a gift from Dr. W. Claycomb (Lousiana State
University Medical Center, New Orleans, LA). The HL-1cells retain ultrastructural
characteristics in vitro of adult atrial cardiac muscle cells, including the ability to
spontaneously contract in culture (Claycomb, 1998). The cells were grown and maintained
as previous described in Claycomb et al. (1998). Briefly, undifferentiated HL-1 cells were
seeded onto 100-mm plates (USA Scientific, Inc.) pre-treated plates with fibronectin
dissolved in 0.02% gelatin and maintained in Claycomb’s Dulbecco's Modified Eagle's
Medium (CDMEM), supplemented with 10% fetal bovine serum (Sigma), 1% antibiotic–
antimycotic (Life Technologies, Grand Island, NY), 1% norepinephrine (Sigma) and 1%
L-glutamine (Sigma). Cells were incubated at 37 °C in a water-saturated atmosphere of
95% air and 5% CO2. Three-day-old cardiac cells were subcultured (transferred) and
allowed to grow in 12-well plates. For all experiments, cells were grown in 12-well plates
except for electrical stimulation studies where 6-well plates were used (USA Scientific,
Inc.). The medium was renewed with fresh culture medium every 1 to 2 days until
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treatment. All treatments were performed on confluent cultures which were spontaneously
contracting.
5.2.1.1. Sample collection for HL-1 cardiac cell
To determine GDNF protein concentrations in culture media, conditioned samples
were collected from each culture dish 30min to 24h following treatments. To harvest cells,
culture medium was removed, cells were washed with Dulbecco’s phosphate buffered
saline (DPBS: Sigma, St. Louis, MO) and 1ml of sample buffer (a mixture of phosphate
buffered saline, 0.005% Tween-20, 0.5% bovine serum albumin, 0.1mM benzethonium
chloride, 2mM benzemidine, 0.4M NaCl, 2mM EDTA and 164µl/100ml aprotinin) was
added. Cells were scraped from the dish using a cell lifter (USA Scientific, Ocala, FL). To
examine intracellular GDNF, cells were spun in a cold centrifuge at 13.5 x g and
supernatant was removed and stored at -20°C. GDNF protein content in each experiment
was measured by an enzyme-linked immunosorbent assay (ELISA) as described in
Vianney and Spitsbergen (2011).

5.2.2. C2C12 cell culturing
The C2C12 mouse skeletal muscle cell line was purchased from American Type
culture collection (ATTC: Manassas, VA, USA). The C2C12 cell line was extracted from
2-month old mouse thigh muscle and have been used by researchers because of their in
vivo skeletal muscle phenotype, including expression of contractile proteins (Ling et al.,
2005; Yafel and Saxel, 1997). C2C12 culturing procedure were performed according to
the ATTC protocols and as described by Vianney and Spitsbergen (2011), with some minor
modifications. Briefly, C2C12 myoblasts were initially seeded on 100-mm plates (USA
Scientific, Inc.) and maintained in Dulbecco’s Modified Eagle’s medium (DMEM: ATCC)
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supplemented with 10% fetal bovine serum (Sigma) and 1% antibiotic-antimycotic (Life
Technologyies, Carlsbad, CA, USA). Cells were incubated at 37°C in water-saturated
atmosphere of 95% air and 5% CO2. For all experiments cells were grown in 12-well plates
except for electrical stimulation studies where 6-well plates were used (USA Scientific,
Inc.). Cells were seeded as myoblasts and differentiation was induced by replacing the
growth medium with DMEM supplemented with 10% horse serum and 1% antibioticantimyocotic. The medium was renewed every one to two days. Myotube studies were
performed on myotubes that had been maintained in culture for 6 to 7 days.
5.2.2.1. Sample collection for C2C12 cells
To determine GDNF protein concentration in culture medium, conditioned samples
were collected from each culture dish at 2, 4, and 24 h following treatment and kept at 20°C. To harvest cells, culture medium was removed, cells were washed with
calcium/magnesium-free buffer and 1ml of sample buffer was added to each culture dish
containing either myoblastas or myotubes. To harvest myoblasts, the cells were scraped
from the dish using a cell lifter (USA Scientific, Ocala, FL). For myotubes, 1ml of sample
buffer was added causing cells to detach from the culture dish. To examine intracellular
GDNF, cells were spun in a cold centrifuge at 13.5 x g and supernatant was removed and
stored at -20°C. GDNF protein content in each experiment was measured by ELISA.
5.2.3. Western blot analysis
To examine size of GDNF protein molecules, culture medium and cell samples
were loaded with Laemmli 2X loading buffer to make a final volume of 20μl. Controls
consisted of a protein ladder (New England BioLabs), GDNF protein (positive control) and
NGF protein (negative control). The samples were boiled for 5 min then loaded into a 15%
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polyacrylamide gel. The gel was submerged and run in separating buffer at two different
voltages, starting at 100V then switched to 150V. The transfer of protein from the gel to
the polyvinylidene difluoride (PVDF; Invitrogen) membrane was performed at 12V for 1h
and 30min. The PVDF membrane was blocked with I-Block (Applied Biosystems, Foster
City, CA, USA) for 1 h at 4 °C on a shaking platform. The membrane was then incubated
with a primary antibody against GDNF (Santa Cruz Biotechnologies) in I-Blocking buffer
solution overnight at 4 °C on a shaking platform. The membrane was washed for 5, 10, and
20 min with 1X phosphate buffered saline (PBS) while shaking. The membrane was then
incubated with a HRP-conjugated secondary antibody (ECL; GE Healthcare) in I-Blocking
buffer for 1 h at room temperature while shaking then washed with 1X PBS. GDNF protein
was detected with chemiluminescence and was visualized on BioMax XAR film (Sigma)
with exposure times of 1-3 min or with luminescence detection machine (Carestreem, GE
Healthcare) with exposure time of 1-15min.

5.2.4. Treatment with acetylcholine
Acetylcholine (ACh) was used because it is the neurotransmitter that is released by
both somatic motor neurons and parasympathetic neurons innervating the heart. For each
experiment, old medium was removed and fresh medium containing 0.1µM, 1µM, or
100µM ACh was added to cells. Conditioned culture medium and harvested cell samples
were taken at 2, 4, and 24 hours following treatments. Control plates were processed the
same except that, no neurotransmitter was added. GDNF protein content was determined
by ELISA.
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5.2.5. Electrical stimulation of the cells
Cells were electrically stimulated as in previous studies (Vianney et al., 2014). Cells
were stimulated at 1Hz or 5Hz with 24V 30ms pulse for 30min – 48hours. All cultures
were maintained at 37°C in water-saturated incubator of 95% air and 5% CO2 during
stimulation periods.

5.2.6. Statistical analysis
Statistical analysis was performed using a Student’s t-test. P values ≤ 0.05 were
considered statistically significant. All data values are reported as the mean  standard error
of the mean (S.E.M).

5. 3. RESULTS
5.3.1. GDNF protein in skeletal and cardiac muscle cells
Results from western blot revealed that both skeletal and cardiac muscle cells
expressed and secreted GDNF with a molecular size approximately 45kDa (Figure 5.1).
Differentiated skeletal muscle cells (myotubes) contained an additional band with
molecular size around 25kDa, and this band was only observed in culture medium samples
(Figure 5.1A). Cardiac muscle cells express GDNF with a single molecular size of 45kDa
(Figure 5.1B).
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GDNF molecular sizes in skeletal and cardiac muscle cells
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Figure 5.1. GDNF molecular sizes in skeletal and cardiac muscle cells. Cells were
grown and allowed to differentiate according to the protocol for each cell type. Samples
were collected from 7-day-old myotubes and 5-day-old cardiac muscle cells. A. Both cell
types express GDNF of ~45kDa. Myotubes release an additional band of ~25kDa. Lane 1,
GDNF positive control show ~45kDa and ~17kDa; Lanes 2-5, two bands, 45kDa and
25kDa of GDNF released by myotubes; Lanes 6-9, intracellular GDNF in myotubes. Lane
10, protein ladder. B. Cardiac muscle cells GDNF with size of ~45kDa; lanes are assigned
as in (A) above.

Skeletal and cardiac muscle cells contained similar amounts of GDNF protein;
however, cardiac cells secreted more GDNF protein (Table 1 and Figure 5.2A). Figure
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5.2B shows percentage contribution to total GDNF by either GDNF secreted or GDNF
retained in cells. Intracellular skeletal muscle GDNF contributed about 87% of total GDNF
produced by myotubes whereas GDNF released into culture medium contributed only 13%
to the total GDNF. In cardiac cells, intracellular GDNF and extracellular GDNF was about
60% and 40% respectively (Figure 5.2B).

GDNF production in skeletal and cardiac muscle cells

A

500

GDNF conc. (pg/ml)

400

*$

300
200

*

100
0
Cell
Cardiac

medium
Skeletal

164

Percentage contribution of intracellular and secreted GDNF
Total GDNF

B 120

% contribution

100
80
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20
0
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Figure 5.2A-B. GDNF production in skeletal and cardiac muscle cells. A, Both cell
types synthesize GDNF protein and both cell types secrete less protein than they retain
inside the cell. Cardiac muscle cells secrete higher levels of GDNF protein than skeletal
muscle cells B. Intracellular GDNF contributes 87% or 62% in skeletal muscle or cardiac
muscle, respectively. Values are presented as mean, S.E.M. Asterisk (*) indicates a
significant difference (P ≤ 0.05) between levels of GDNF that is retained in cells and GDNF
that is secreted in culture medium in each cell type. A dollar sign ($) indicates a significant
difference between cell lines, N=8.
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Table 5.1: Ratios of synthesized to secreted GDNF

Skeletal muscle cells
Time
30min
1h
2h
4h
8h
12h
24h

synthesis
281
376
313
474
566
473

secretion
55*
29*
30*
67*
64*
137*

Cardiac muscle cells
ratio

synthesis
5
13
10
7
9
3

secretion ratio

497
432
324
461
398

287*
243*
139*
285*
284*

1.7
1.8
2
1.6
1.4

256

197*

1.3

GDNF synthesis and secretion concentration in pg/ml

Table 5.1. GDNF synthesis and secretion in skeletal muscle and cardiac muscle
control cells. The table shows the ratio between intracellular and secreted GDNF by
skeletal and cardiac muscle cells. Levels of GDNF secreted by skeletal muscle cells varies
with time. The lowest levels appeared to be at 2h and 4h as the ratio between intracellular
GDNF and GDNF secreted is higher compared to other time points. Unlike skeletal muscle
cells, the intracellular GDNF and GDNF that is secreted in cardiac cells is almost a 1:2
ratio. Asterisk (*) indicates significance difference between GDNF protein in cells and
GDNF secreted into culture medium in both cell types, N=8.
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5.3.2. Effect of ACh on GDNF expression by skeletal and cardiac muscle cells
Treatment with ACh had a similar effect on GDNF production in both cardiac and
skeletal muscle cells. Following 2h treatment at both concentrations (1µM and 100µM)
GDNF secretion was inhibited in both cell types, the effect was much greater in cardiac
muscle cells than in skeletal muscle cells (Figure 5.3A). Treatment with ACh also
decreased intracellular GDNF content in cardiac cells, whereas there was no effect on
intracellular GDNF in skeletal muscle cells (Figure 5.3B).

Effect of acetylcholine on GDNF production in skeletal and cardiac muscle cells
GDNF content in culture medium

A 100
*
*

% control

80
60

*$
40

*$
20
0
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cardiac
1µM

skeletal

cardiac
100µM
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B 120

GDNF content in cells

100

*$

% control

80
60

*$

40
20
0
skeletal

cardiac
1µM

skeletal

cardiac
100µM

Figure 5.3. Effect of ACh on GDNF production by skeletal and cardiac muscle cells.
Cells were plated and allowed to differentiate into myotubes (skeletal) or beating cells
(cardiac). Culture medium containing 1µM or 100µM ACh was added to 7-day-old
myotubes or 5-day-old cardiac cells. A. ACh inhibits GDNF secretion in culture medium
in both cell types although GDNF levels are more reduced in cardiac cells compared to
skeletal muscle cells. B. ACh affects intracellular GDNF levels in cardiac muscle cells but
had no effect on intracellular GDNF in skeletal muscle cells. GDNF protein concentration
was determined by ELISA. Values are presented as Mean ± S.E.M. An asterisk (*)
indicates a significant deference from control and the dollar sign ($) indicates a significant
difference between cell types (P ≤ 0.05), N = 6.
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5.3.3. Effect of electrical stimulation on GDNF expression in skeletal and cardiac
muscle cells
We examined the effect of electrical impulses on GDNF expression in skeletal
muscle and cardiac muscle cells. Thirty minutes of electrical stimulation at 1Hz caused an
increase in GDNF secretion in cardiac muscle cells and a decrease in GDNF secretion in
skeletal muscle cells (Figure 5.4). When the duration of electrical stimulation was
increased from 30 minutes to 48 hours, levels of secretion of GDNF by cardiac cells are
significantly inhibited compared to control, while GDNF secretion in skeletal muscle is
significantly increased compared to control (Figure 5.5A). Intracellular GDNF content was
altered in a similar manner to secreted GDNF in both cell types following low frequency
stimulation (data not shown). Skeletal muscle cells showed a similar response to high
frequency stimulation (5Hz) as low stimulation; however, cardiac muscle cells, displayed
a decline in GDNF secretion (Figure 5.5B) and intracellular content (data not shown) at all
times following stimulation at 5Hz.
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Effect of short-term electrical stimulation on skeletal and cardiac muscle cells
GDNF content in culture medium
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cardiac

24h

Figure 5.4. Opposite effect on GDNF secretion in skeletal and cardiac muscle cells
following 1Hz electrical stimulation for 30minutes. Cells were plated on 6-well plates
and allowed to differentiate. Electrical stimulation for 30min at low frequency (1Hz) have
opposite effects on GDNF production by skeletal and cardiac muscle. GDNF protein
concentration was determined by ELISA. Values are presented as Mean ± S.E.M. Asterisk
(*) indicates a significant increase from control, the pound sign (#) a significant decrease
from control, and the dollar sign ($) a significant difference between skeletal muscle and
cardiac muscle, (P ≤ 0.05), N=6.
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Effect of 1Hz on GDNF production by muscle cells

GDNF content in culture medium

A

skeletal
cardiac

160
140
% control

120
100
80
60
40
20
0
30min

90min

12h

24h

48h

Duration of Stimulation
Figure 5. 5A. Effect of short- and long-term electrical stimulation on GDNF
production in skeletal and cardiac muscle – effect of 1Hz. Cells were electrically
stimulated at 1Hz for 30min, 90min, 12h, 24h, and 48h at 1Hz. With short-term ES, the
excitatory effect in cardiac muscle cells or inhibitory effect in skeletal muscle cells are
reduced as the duration of ES is increased. With long-term ES the inhibitory effect in
skeletal muscle becomes a stimulatory effect and the early stimulatory effect in cardiac
muscle becomes inhibitory. Electrical stimulation at 1Hz has a similar effect on
intracellular GDNF of both skeletal and cardiac muscle cells (data not shown). GDNF
protein content was determined by ELISA. Values are presented as mean ± S.E.M. (P≤
0.05). N=6
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Effect 5Hz frequency on GDNF secretion
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%control
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24h
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Duration of Stimulation
Figure 5.5B. Effect of short- and long-term electrical stimulation on GDNF
production in skeletal and cardiac muscle - effect of 5Hz. Cells were electrically
stimulated at 5Hz for 30min, 90min, 12h, 24h, and 48h at 5Hz. In skeletal muscle cells ES
at 5Hz causes an early inhibition of GDNF production that transitions to a stimulatory
effect with long-term ES. Stimulation of cardiac muscle cells at 5Hz leads to an inhibition
of GDNF production at all times. The 5Hz frequency has similar effect on intracellular
GDNF in both skeletal and cardiac muscle cells (data not shown). GDNF protein content
was determined by ELISA. Values are presented as mean ± S.E.M. (P≤ 0.05), N=6.
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5. 4. DISCUSSION

In the current study, we have examined GDNF production in voluntary and
involuntary muscle cells. The pattern of GDNF protein expression in control muscle cell
types was assessed, and changes in expression following chemical or electrical stimulation
was quantified. The overall results show that 1) both skeletal muscle and cardiac muscle
cells express approximately equal amounts of intracellular GDNF protein. However, the
amount secreted into culture medium by both cell types differs. 2) Acetylcholine, the
neurotransmitter released by somatic and parasympathetic neurons, inhibits GDNF
production in skeletal and cardiac muscle cells. 3) Direct electrical stimulation (ES) has
opposing effects of GDNF expression in skeletal muscle and cardiac muscle cells. The
results suggest that GDNF production in skeletal muscle and cardiac muscle is dependent
on ongoing activity. Also, the results demonstrate that the same stimulus may exert very
different effects on GDNF production in different muscle types. These effects depend on
the duration of exposure, intensity, or concentration of stimulus. Skeletal muscle and
cardiac muscle cells express GDNF of the same molecular weight, although the cleavage
and secretion processing may differ between the cell types.
Skeletal muscle and cardiac muscle cells express GDNF protein of molecular weight
about 45kDa, which may represent a dimerized form of activated GDNF (Xu et al., 1998).
Skeletal muscle cells also appear to release GDNF of molecular size about 25kDa, which
may represent the monomer form of GDNF (Xu et al., 1998). This monomer form of GDNF
was only observed in the skeletal muscle culture medium. On the other hand, cardiac
muscle cells synthesize and secrete the dimerized form of GDNF. Both the dimer and
173

monomer forms may represent pro-GDNF, the precursor form of active GDNF (Xu et al.,
1998). Other studies have shown that a number of other cell types secrete pro-GDNF
(Lonka-Nevalaita et al., 2010) and the proteolytic cleavage of the mature pro-protein can
occur either inside the cell or outside the cells, or both (Lonka-Nevalaita et al., 2010; Teng
et al., 2005). Because of the GDNF molecular size observed in the current study, it appears
as though both differentiated skeletal muscle cells and cardiac muscle cells may release
pro-GDNF. Our western blot did not detect GDNF in the final mature form (15 to 20 kDa),
a form in which both pre- and pro- amino acid portions have been cleaved. This may
suggest that GDNF expressed in skeletal muscle and cardiac muscle are released in proforms and undergo cleavage after being released. The pro-forms of neurotrophins (both
pro-BDNF and pro-NGF) have been shown to play a role in apoptotic pathway in cells
(Teng et al., 2005). However, a study conducted by Kust et al. (2014) investigating the
effect of mature GDNF and its precursors (pre-GDNF, pro-GDNF, pre-pro GDNF) on
spinal ganglia cells, demonstrated that these GDNF forms exert trophic support on neuronal
growth, although at different degrees. The mature GDNF was show to have the maximum
trophic effect on neuronal growth with pro-GDNF having the least trophic effect (Kust et
al., 2014). Moreover, as stated earlier, cardiac muscle cells have been shown to release
only dimerized GDNF, whereas differentiated skeletal muscle release both the monomer
and dimer GDNF. Since different biological activities of neurotrophin monomers and
dimers have been proposed (Kolbeck et al., 1994), this suggests that there may be
similarities and differences in function of GDNF in skeletal muscle and cardiac muscle.
The results also suggest that GDNF processing within skeletal and cardiac muscles
may differ. Skeletal muscle cells show a higher ratio of intracellular to extracellular GDNF,
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where cardiac cells secrete a much higher ratio of the GDNF being produced. The
differences between cardiac muscle cell GDNF and skeletal muscle cell GDNF handling
may suggest constitutive and regulated pathways (Nevalaita and Saarma, 2010), where in
cardiac muscle transport vesicles containing GDNF fuse immediately in the cell membrane
upon arrival, while GDNF in skeletal muscle may accumulate at the target membrane until
the cells are triggered to release it. The secretion pattern of GDNF observed in skeletal and
cardiac muscle cells in the current study, may explain why GDNF levels in skeletal muscle
increase with increased activity (Gyorkos et al., 2014; Gyorkos and Spitsbergen, 2014;
Vianney et al., 2014), whereas in cardiac cells the prolonged activity leads to a decline in
GDNF. The proposed regulated and constitutive mechanisms of secretion for GDNF in
skeletal muscle cells and cardiac muscle cells may also correlate with the contractile
characteristics of skeletal (voluntary) muscle and cardiac (involuntary) muscle.
Our results support previous in vitro and in vivo studies where increased electrical
stimulation of skeletal muscle or increased intensity of exercise in rats increased GDNF
production in skeletal muscle cells or skeletal muscle fibers (Gyorkos and Spitsbergen,
2014; Vianney et al., 2014). On the other hand, in cardiac cells, GDNF declines as the
duration or intensity of stimulation increases, suggesting that the cardiac cells have a
mechanism that prevents an increase in GDNF expression with chronic activity or high
intensity activity. This limit on trophic factor production may be due to the fact that
overexpression of neurotrophic factors in the heart is not always desirable (Ieda and
Fukuda, 2009). The effects of electrical stimulation in the current study also demonstrates
that the same stimulus may induce very different effects on GDNF production in voluntary
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and voluntary muscles and that, duration and/or intensity of exposure are critical
determinants of the effect on GDNF production.
ACh negatively regulates GDNF secretion in both muscle cell types. However, in
cardiac muscle cells both intracellular and secreted GDNF protein levels are decreased
following ACh treatment. The mechanism underlying the inhibition of GDNF in both
skeletal muscle and cardiac muscle cells has yet to be determined. However, the same
observations have been observed with other ACh studies. In developing NMJ, ACh
regulates NMJ in a negative fashion by inhibiting extra synaptic growth (An et al., 2010);
or, by causing a decrease in acetylcholine receptors that are spontaneously formed at the
NMJ (Lin et al., 2005; Xiong and Lin, 2005). Similarly, in vitro studies suggest thatACh
inhibits GDNF in skeletal muscle (McCullough et al., 2011; Vianney et al., 2014).
Therefore, it can be postulated that the presence of ACh functions by preventing extra
production of the NMJ components including some of the neurotrophic factors produced
by a muscle target. Figure 7 attempts to illustrate an event or a relationship of the synaptic
components that have been reported to be associated with GDNF at the NMJ. Both GDNF
and its receptors are expressed in skeletal muscle, this suggests an autocrine mode of action
of GDNF, whereby GDNF enhances the insertion of AChRs in the absence of innervation
(Young and Nelson, 2004) When ACh is present it acts to inhibit AChR insertion, which
indirectly inhibits the action of GDNF on enhancing the insertion of AChRs. The same
mechanism of action may also be true in cardiac muscle.
We believe that the current study is the first to examine the regulation of GDNF
production in voluntary and involuntary muscles. Our results show that ACh alters GDNF
production in cardiac and skeletal muscles, suggesting that somatic and autonomic nervous
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system may be involved in regulation of GDNF production in the heart and skeletal muscle.
The effects of electrical stimulation, which bypasses the neurotransmitter signaling steps
at the neuromuscular junction events following muscle depolarization, are also important
regulators of GDNF expression in the target tissues.
Because GDNF is a naturally occurring neurotrophic factor and provides trophic
support for the nervous system, understanding endogenous factors that control GDNF
production may help to explain why diseases associated with neural-target dysfunction
occur. Furthermore, determining the similarities and differences on how GDNF expression
is regulated in target tissues may also provide a better understanding of how these processes
may be modulated therapeutically. However, further studies are needed to determine the
potential mechanism(s) responsible for differential regulation of GDNF in voluntary and
involuntary muscle cells.
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5.5. SUMMARY


The study compares the regulation of production of GDNF in voluntary
(skeletal) muscle and involuntary (cardiac) muscle following electrical
and chemical stimulation.



Results suggest that electrical stimulation has opposing effects on GDNF
production in cardiac muscle and skeletal muscle. GDNF levels increase
with long-term electrical stimulation in skeletal muscle and decrease with
the long term electrical stimulation in cardiac muscle.



Treatment with acetylcholine inhibits GDNF production in both cardiac
and skeletal muscle cells.



The current results suggest that GDNF expression may be differentially
regulated in the heart and skeletal muscle. Therefore:



Understanding the regulation of GDNF production in these target tissues
will provide a better understanding of how these processes may be
modulated therapeutically.
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CHAPTER 6
SUMMARY, CONCLUSION, AND FUTURE STUDIES

6.1. REGULATION OF GDNF EXPRESSION IN A NERVE-MUSCLE COCULTURE SYSTEM
The overall goal of this study was to investigate whether neural cells control their
own supply of muscle-derived GDNF. Preliminary studies showed that GDNF production
was inhibited in co-cultures of skeletal muscle myotubes and cholinergic neurons as GDNF
content in co-cultured cells declined compared to controls. Also, immunocytochemical
staining using anti-GDNF showed that cholinergic neurons grown with skeletal muscle
myotubes were stained positive for GDNF, whereas, these neurons did not contain GDNF
when they were grown alone. Why cholinergic neurons appear to contain GDNF when in
contact with skeletal myotubes is not clear. Further studies are needed to investigate
whether:
1. Cholinergic neural cells express GDNF when in contact with skeletal myotubes. In
situ hybridization is one of the useful experiments that allows one to examine gene
expression at the mRNA level. Thus, studies aimed at examining which cell type,
(neural cells, skeletal myotubes, or both) are expressing GDNF mRNA will give
more insight into how target-derived GDNF production is regulated.

2. GDNF protein secreted by skeletal myotubes is taken up by neural cells. One of the
experiments to examine this hypothesis may involve growing neural cells and
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muscle in compartment chambers (Klusch et al., 2013) and use retrograde tracing
methods (Choi et al., 2002) to detect retrograde transport of GDNF.

6.2. GDNF SYNTHESIS/SECRETION PATTERNS IN SKELETAL AND
CARDIAC MUSCLE CELLS
We have examined GDNF production in voluntary and involuntary muscles using
skeletal and cardiac muscle cells, respectively. Overall findings show that both cell types
synthesize equal amounts of GDNF but the cells differ in secretion of GDNF. While
skeletal muscle myotubes release less than a quarter of the total GDNF they produce,
cardiac muscle cells release almost a half of the total GDNF produced. This suggests that
GDNF secretion pathways in voluntary and involuntary muscles may differ. One
possibility is that skeletal muscle GDNF secretion may be regulated, whereas in cardiac
muscle, GDNF may be constitutively released. However, it is not clear whether skeletal
muscle normally secretes low levels of GDNF, as it was observed in the current study; or,
the low levels of secreted GDNF may be caused by a defect in GDNF protein variants (the
two forms of GDNF) processing that has been observed in other cell models (LonkaNevalaita et al., 2010; Oh-Hash et al., 2009). Therefore, further studies may be needed to
examine whether:
3. a) The two forms of GDNF mRNA and corresponding GDNF protein are expressed
in skeletal and cardiac muscles in vivo and in vitro using PCR/RT-PCR and western
blot analysis.
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b) Both regulated and constitutive pathways of GDNF exist in skeletal and cardiac
muscles. Immunocytochemical techniques may help detect which form of
GDNF is localized in regulated and/or constitutive vesicles (Geng et al., 2011;
Lonka-Nevalaita et al., 2010)

6.3. SOMATIC AND AUTONOMIC NEURONS REGULATE NEUROTROPHIC
FACTOR PRODUCTION VIA NEUROTRANSMITTER EFFECTS
Table 6. 1: Effect of neurotransmitters and electrical stimulation on GDNF and NGF
production in cardiac muscle cells.

SHORT-TERM EFFECT
GDNF

NGF

LONG-TERM EFFECT
GDNF

NGF

ACh

1µM
100µM







NE

0.1mM
1mM




no effect
no effect




no effect


ES

1Hz
5Hz













ACh: acetylcholine; NE: Norepinephrine; ES: Electrical Stimulation. An upward ()
represents an increase in neurotrophic factors production and a downward arrow ()
represents a decrease in neurotrophic factors.
Table 6.1. Summary of results of short- and long-term treatment with
neurotransmitter or electrical stimulation on GDNF and NGF production by HL-1
cells.
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Acetylcholine (ACh): Both low and high concentrations of ACh inhibit GDNF
production, while a low concentration of ACh stimulates NGF production and a high
concentration of ACh inhibits it. Norepinephrine (NE): Both low and high concentrations
of NE stimulate GDNF production. Short-term and long-term exposure to NE had no effect
on NGF production. Electrical stimulation (ES): Short-term ES at low frequency (1Hz)
increases both GDNF and NGF production and long-term stimulation decreases production
of the neurotrophic factors. High frequency (5Hz) exerts similar effect on NGF production
as that of low frequency stimulation. GDNF production is inhibited following both shortand long-term electrical stimulation when cells are stimulated at 5Hz.

6.3.1. Acetylcholine regulates GDNF production in skeletal and cardiac muscles
Cholinergic neurons inhibit GDNF expression in skeletal muscle (Vianney and
Spitsbergen, 2011). Similarly, ACh inhibits GDNF production in both, skeletal muscle and
cardiac muscle, suggesting that cholinergic neurons regulate GDNF in the muscle via ACh
release. However, the mechanism underlying ACh inhibition of GDNF expression remains
unclear. Lie and Weis (1998) observed that the amount of GDNF mRNA levels increased
in denervated muscle compared to innervated muscle. Moreover, GDNF mRNA and
GDNF protein levels were shown to increase after nerve injury and during nerve
regeneration process, but the levels returns to normal with reinnervation (Naveilhan et al.,
1997; Suzuki et al., 1998; Michalski et al., 2008; Yamada et al., 2004). All of the above
may suggest that the reduction of GDNF protein production observed with an intact neural
connection may be due to an inhibitory effect of ACh on GDNF expression in skeletal and
cardiac muscle. However, this is one of possible potential mechanisms of action of GDNF.
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Thus, further studies aimed at understanding normal regulatory process and GDNF
expression levels may help understand and draw better conclusion with changes of GDNF
observed with experimental treatments. Therefore:
4. Cross sectional and/or longitudinal studies could be performed to investigate the
following broad questions:
a) What is the ongoing need for GDNF protein in tissue from healthy humans and
model organisms?
b) Do different types of tissues normally differ in their GDNF protein content?
c) When are changes in GDNF protein content or mRNA observed in tissues
following aging or with development of disease?
d) In (a) – (c) above, are there differences between different GDNF isoforms?
The possibility that GDNF may be acting in autocrine mode is another potential
mechanism that may lead to decreased production of GDNF in these studies. GDNF
autoregulation has been reported in neuronal cells in vivo and in vitro, where GDNF acts
to increase its own expression (Barak et al., 2011; He and Ron, 2006). It may be interesting
to examine:
5. Whether GDNF autoregulatory system exists in skeletal muscle and cardiac
muscle. To do this, GDNF receptors (GFRα1) on the muscles may be blocked with
anti- GFRα1 antibodies Ab1531 and/or AbG90 (Messer et al., 2000). Short-term
electrical stimulation or ACh treatments may be performed on skeletal muscle cells
(myotubes) in the presence of anti-GFRα1 antibodies. The hypothesis being tested
is that the inhibitory effect that is observed with a short-term electrical stimulation
or ACh is abolished when GDNF receptors are blocked.
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6.3.2. ACh and norepinephrine have different effects on GDNF and NGF in cardiac
muscle
Overall, the concentration and/or duration of exposure to a neurotransmitter are
important in determining the direction of changes in GDNF and NGF expression in cardiac
muscle. Moreover, levels of expression of GNDF and NGF are regulated differently by
ACh and NE in cardiac muscle. While GDNF protein levels decrease with exposure to
ACh, the levels increase with exposure to NE.

6. Studies aimed at determining the relationship between the rate of cardiac muscle cell
contraction and levels of GDNF or NGF production may be valuable. In these studies
changes in cardiac cell contraction may be modulated by addition of neurotransmitters,
electrical stimulation, or other depolarizing agents such as potassium chloride (KCl).

6.4. ELECTRICAL STIMULATION REGULATES NEUROTROPHIC FACTORS
PRODUCTION IN SKELETAL AND CARDIAC MUSCLES

6.4.1. Electrical stimulation has different effects on GDNF production in skeletal and
cardiac muscles.
As shown in Chapter 5, Figure 5.5A, the response to electrical stimulation at 1Hz
in skeletal and cardiac muscle is almost a mirror image, where short-term electrical
stimulation inhibits GDNF production in skeletal muscle and increases GDNF production
in cardiac muscle, while long-term stimulation increases GDNF production in skeletal
muscle and decreases it in cardiac muscle. The mechanisms underlying the effect on GDNF
production following short- and long-term electrical stimulation remain unclear. A further
investigation examining these mechanisms may be based on the following assumptions:
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7. a)

It is well known that electrical stimulation produces changes in contractile

proteins such as myosin heavy chain in vivo and in vitro (MHC: Bayol et al., 2005).
Mature C2C12 myotubes are known to express predominantly fast MHC (Brown
et al., 2012; Zebedin et al., 2004) and a switch from fast to slow MHC in C2C12
skeletal myotubes has been shown to be induced by chemical or electrical
stimulation (Zebedin et., 2004). It may be of interest to examine whether changes
in GDNF protein levels observed with electrical stimulation are due to changes in
muscle characteristics, such as a switch from fast to slow MHC.

b) Results from (a) above, may help explain whether or not the regulation of GDNF
expression depends only on the duration and intensity of the stimulus or whether
GDNF expression is linked to the muscle fiber composition.

8. Another observation was that electrical stimulation did not induce contraction in 9to 14-day-old myotubes, yet there was a significant change in GDNF protein
following stimulation. Similarly, treatment with acetylcholine or carbachol did not
cause myotube contraction, however, there was a significant change in GDNF
protein levels with treatment.

Also treatment with a high concentration of

carbachol decreases contraction in cardiac muscle cells. Thus, it may be
hypothesized that changes in GDNF protein production in skeletal and cardiac
muscles does not only depend on contractile activity, but may also depend on
changes in other intracellular signals that occur with stimulation. Therefore, it may
be reasonable to examine:
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a) The role that ion channels play in the processes regulating GDNF production in
skeletal and cardiac muscles.

9.

Many cells express GDNF mRNA splice variants and their corresponding proteins
(α-GDNF and β-GDNF) (Lie and Weis, 1998; Lonka-Nevalaita et al., 2010; OhHash et al., 2009; Springer et al., 1995). Secretion of these GDNF isoforms has
been shown to differ in cell models. Studies by Lonka-Nevalaita et al., (2010)
observed that potassium chloride increases secretion of β-GDNF but not α-GDNF
in PC-6.3 cells. Whether the different in secretion of GDNF forms is observed in
skeletal and cardiac muscle is not known, therefore a study aimed at examining:

a) Whether treatments with neurotransmitter, electrical stimulation, or other
depolarizing agents favor secretion of one form of GDNF and if,
b) Rise or fall of intracellular calcium may be involved. Since a number of cellular
processes, including gene expression and muscle contraction, are regulated
calcium, it is possible that GDNF release may be triggered by a rise or fall in
calcium. Changes in GDNF mRNA and/or protein content can be examined
along with intracellular Ca2+ concentration. Changes in intracellular Ca2+ can
be triggered by neurotransmitter and by electrical stimulation. Changes in
intracellular calcium may be blocked by thapsigargin (Engedal et al., 2013).
The concentration of intracellular Ca2+ may be measured by various techniques
either fluorescence or bioluminescence calcium indicators depending on study
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goals and models to be used (Cobbold and Rink, 1987; Engedal et al., 2013;
Grienberger and Konnerth, 2012; Russell, 2011; Tahakashi et al., 1999).
Overall, this study demonstrates that there are some similarities and differences in
regulation of GDNF production in voluntary and involuntary muscles. These differences
appear to depend on duration and intensity of exposure. Understanding the similarities and
differences in the regulation of GDNF production in different tissues may provide a better
understanding of how GDNF production may be modulated therapeutically.
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